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Abstract
ELUCIDATING THE ROLE OF APL-1, THE C. ELEGANS ORTHOLOG OF THE HUMAN
AMYLOID PRECURSOR PROTEIN
by
Adanna G. Alexander
Advisor: Dr. Christine Li

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, impacting
approximately 6 million Americans. AD is the leading cause of dementia amongst the aged
population. Post mortem analysis of the brains of AD patients shows high quantities of
extracellular Aβ peptide deposits, which are derived from cleavage of the amyloid precursor
protein (APP). Mutations in APP and proteins responsible for APP cleavage, PSENs, greatly
increase the incidence of developing AD at an early age. Despite its strong correlation to the
progression of AD, the role of APP remains unclear.
Here we investigate the role of the Caenorhabditis elegans ortholog, APL-1. We
identified approximately 40 proteins that interact with APL-1, and two genes that modify apl-1
activity. In particular, we showed that the heparan sulfate proteoglycan, UNC-52, is complexed
with APL-1, and mutations in apl-1 enhance unc-52 phenotypes. We speculate that UNC-52 is
required to sequester secreted APL-1 to help maintain APL-1-receptor interactions.
Additionally, we generated two allelic mutants that showed that cdh-5 and/or tgt-1 modify apl-1
activity. These interacting proteins suggest that APL-1/APP is involved in numerous cellular
functions; maintaining APL-1/APP levels impact embryonic development and lifespan. Our
findings inform on the function and interactions of mammalian APP.
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Chapter I: Introduction

Use of Caenorhabditis elegans as a model to study Alzheimer’s
disease and other neurodegenerative diseases
Adanna G. Alexander 1,2 †, Vanessa Marfil 1 † and Chris Li 1,2 *
1

Department of Biology, City College of New York, New York, NY, USA
Department of Biology, The Graduate Center, City University of New York, New York, NY,
USA
2

1.1 Article summary
Advances in research and technology has increased our quality of life, allowed us to combat
diseases, and achieve increased longevity. Unfortunately, increased longevity is accompanied by
a rise in the incidences of age-related diseases, such as Alzheimer’s disease (AD). AD is the
sixth leading cause of death, and one of the leading causes of dementia amongst the aged
population in the USA. It is a progressive neurodegenerative disorder, characterized by the
prevalence of extracellular Aβ plaques and intracellular neurofibrillary tangles, derived from the
proteolysis of the amyloid precursor protein (APP) and the hyperphosphorylation of
microtubule-associated protein tau, respectively. Despite years of extensive research, the
molecular mechanisms that underlie the pathology of AD remain unclear. Model organisms, such
as the nematode, Caenorhabditis elegans, present a complementary approach to addressing these
questions. C. elegans has many advantages as a model system to study AD and other
neurodegenerative diseases. Like their mammalian counterparts, they have complex biochemical
pathways, most of which are conserved. Genes in which mutations are correlated with AD have
counterparts in C. elegans, including an APP-related gene, apl-1, a tau homolog, ptl-1, and
1

presenilin homologs, such as sel-12 and hop-1. Since the neuronal connectivity in C. elegans has
already been established, C. elegans is also advantageous in modeling learning and memory
impairments seen during AD. This article addresses the insights C. elegans provides in studying
AD and other neurodegenerative diseases. Additionally, we explore the advantages and
drawbacks associated with using this model.

1.2 Introduction to Alzheimer’s disease
AD is a neurodegenerative disease characterized by a progressive loss of memory.
Approximately 5.8 million Americans suffer from Alzheimer’s-related dementia (Gaugler et al.,
2019). Among 5.6 million of this population, AD occurs sporadically without a clear inheritance
pattern in aged individuals ≥65 years (late-onset AD) (Gaugler et al., 2019). By contrast, earlyonset or familial AD appears in ~200,000 individuals, who are <65 years old (Gaugler et al.,
2019). Both forms of AD have two main neuropathologic features that begin developing
approximately 20 years before Alzheimer’s-associated symptoms are apparent: the presence of
extra-neuronal amyloid plaques, often referred to as senile plaques, and intraneuronal
neurofibrillary tangles (Kidd, 1964; Krigman et al., 1965; Luse and Smith, 1964; Terry et al.,
1964). Amyloid plaques are aggregates of the beta-amyloid peptide (Aβ), a cleavage product of
the amyloid precursor protein (APP) (Glenner and Wong, 1984; Kang et al., 1987; Masters et al.,
1985). Hyperphosphorylation of the microtubule associated protein tau causes its polymerization
into paired helical filaments and, presumably, its formation into neurofibrillary tangles (Goedert
et al., 1989a).
Mutations in the APP gene and/or the enzymes involved in APP processing (γ-secretase
components presenilins, PSEN1 and PSEN2) (Chartier-Harlin et al., 1991; Goate et al., 1991;
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Levy-Lahad et al., 1995; Murrell et al., 1991; Rogaev et al., 1995; Sherrington et al., 1995) are
correlated with early-onset AD. These mutations increase the levels of toxic Aβ species and
promote neurodegeneration. For example, the autosomal dominant mutation in PSEN1, E280A,
results in early-onset AD occurring at 46.8 ± 6.4 years (mean ± SEM), and age at death of 54.8 ±
7.3 years (mean ± SEM) (Lopera et al., 1997). A newly identified protein, aggregatin, is present
at the core of the senile plaques to assist with the Aβ aggregation (Yan et al., 2020). By contrast,
a mutation in APP that affects cleavage of APP causes less Aβ production and confers
neuroprotective benefits (Jonsson et al., 2012). Despite the significant advances made using
APP transgenic and knockout models in mammals, unraveling the cellular role of APP has been
difficult. Alternative animal models provide complementary approaches to dissecting the
function of APP and tau. In this review, we discuss the latest uses of the nematode
Caenorhabditis elegans as a model system for the study of AD.

1.2.1 C. elegans as a model for Alzheimer’s disease
C. elegans is a free-living, non-parasitic nematode that was first introduced as a model
organism by Sydney Brenner in 1963 (Brenner, 1974). It is a small (1 mm in length), transparent
roundworm, which makes it easy for manipulation, and has a short life cycle of 3 days from egg
to adult at 25oC (Brenner, 1974). Under suitable growing conditions, hatched animals develop
through four larval stages (L1 to L4), each punctuated by a molt, to arise as an adult
hermaphrodite with 959 somatic cells (Sulston, 1983; Sulston and Horvitz, 1977). Its life span is
between 2 to 3 weeks, which facilitates the study of its biology. Completion of the C. elegans
genome sequence in 1998 (C. elegans Sequencing Consortium, 1998) demonstrated that roughly
38% of worm genes have a human ortholog, such as APP and tau (Shaye and Greenwald, 2011).
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Hence, C. elegans has many excellent advantages as an in vivo model for the study of AD and
other neurodegenerative diseases.

1.3 Molecular pathways of APP. Similarities and differences between mammals and C.
elegans
1.3.1 Processing of APP: non-amyloidogenic and amyloidogenic-Aβ pathway
In mammals, APP is processed through two proteolytic pathways, only one of which
produces Aβ (Fig. 1B) (Haass et al., 1992, 1994a, 1994b). In the non-amyloidogenic pathway,
APP is first cleaved within the Aβ sequence by an α-secretase to release an extracellular
fragment, sAPPα (Fig. 1B). The remaining APP fragment (known as APP-CTFα or C83) is then
cleaved by the γ-secretase complex to release the APP intracellular domain (AICD) to the
cytosol. By contrast, in the amyloidogenic pathway, after cleavage by the β-secretase (BACE) to
release sAPPβ, the remaining APP fragment (known as APP-CTFβ or C99) is then cleaved by
the γ-secretase complex, liberating Aβ to the lumen and AICD to the cytosol (Gu et al., 2001;
Sastre et al., 2001; Weidemann et al., 2002). This latter pathway is likely favored in AD patients.
γ-secretase is a protease complex consisting of several components: presenilins 1 and 2
(PSEN1 and PSEN2), nicastrin (NCT), anterior pharynx defective (APH-1), and the presenilin
enhancer (PEN-2) (Francis et al., 2002; Yu et al., 2000). PSEN1 and PSEN2 are the catalytic
components of the γ-secretase complex. NCT works as a stabilizing cofactor required for γsecretase complex assembly and trafficking (Li et al., 2003; Zhang et al., 2005) and PEN-2 and
APH-1 have a role in the maturation process of PSEN1 and PSEN2 (Luo et al., 2003). Besides
APP, the γ-secretase complex is also involved in the proteolysis of Notch receptors, and the first
identification of any PEN-2 or APH-1 ortholog was in C. elegans as the result of a genetic screen
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for modifiers of the Notch pathway (Francis et al., 2002; Goutte et al., 2002). Within the γsecretase complex, only mutations in PSEN1 and PSEN2 have been associated with early-onset
AD (Levy-Lahad et al., 1995; Rogaev et al., 1995; Sherrington et al., 1995).
In C. elegans there is only one APP ortholog, APL-1. Like human APP (Kang et al., 1987),
APL-1 contains a large extracellular region whose conserved E1 and E2 domains share 46% and
49% sequence similarity to human APP, respectively, a transmembrane domain, and a relatively
small intracellular domain, which shares 71% sequence similarity to human APP (Fig. 1A)
(Daigle and Li, 1993). Notably, unlike APP but similar to APLP1 and APLP2, APL-1 does not
contain the Aβ sequence (Daigle and Li, 1993).
Two α-secretase proteins are present in C. elegans, SUP-17 and ADM-4 (Jarriault and
Greenwald, 2005). They work redundantly in the cleavage of the C. elegans Notch homologues,
LIN-12 and GLP-1 (Jarriault and Greenwald, 2005). However, no experiments thus far have
tested whether SUP-17 or ADM-4 cleaves APL-1. No BACE ortholog has been identified by
bioinformatic searches and no β-secretase activity that cleaves human APP has been detected in
C. elegans, suggesting that APL-1 is only processed by the α/γ-secretase processing pathway
(Link, 2006). α-secretase cleavage of APL-1 releases the extracellular fragment, sAPL-1;
subsequent cleavage of APL-1-CTFα by the γ-secretase complex liberates the intracellular
domain (AICD) (Fig. 1B).
The initial characterizations of human PSEN1 (then called S182) and PSEN2 (first named
E5-1) described them as novel proteins with multiple transmembrane domains (Rogaev et al.,
1995; Sherrington et al., 1995). The cellular functions of the presenilins were determined by
their homology to the C. elegans protein, SEL-12 (Levitan and Greenwald, 1995). The two C.
elegans Notch genes, lin-12 and glp-1, are involved in many cell fate decisions during
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development, including vulval cell specification and germline development (Austin and Kimble,
1987; Greenwald et al., 1983; Lambie and Kimble, 1991; Newman et al., 1995). sel-12/PSEN
was identified in a genetic screen to isolate suppressors of a dominant LIN-12/Notch multivulva
phenotype (Levitan and Greenwald, 1995). Loss of sel-12/PSEN suppressed the LIN-12/Notch
multivulva phenotype and produced a defect in egg laying that was rescued by introducing
human PSEN1 or PSEN2, suggesting a conserved function between human and C. elegans
presenilins (Levitan and Greenwald, 1995; Levitan et al., 1996). Like human PSENs
(Thinakaran et al., 1996), SEL-12/PSEN is cleaved to attain its final topology (Li and
Greenwald, 1996). A C. elegans PSEN family was identified and includes sel-12, hop-1, and
spe-4 (Levitan and Greenwald, 1995; L’Hernault and Arduengo, 1992; Li and Greenwald, 1997;
Westlund et al., 1999); spe-4 is exclusively expressed in male gonadal cells and will not be
further discussed (Arduengo et al., 1998). Knockdown of hop-1/PSEN in sel-12/PSEN mutants
showed maternal effect lethality, germline defects, and missing anterior pharynx, defects
associated with loss of glp-1/Notch function, suggesting that sel-12 and hop-1 function
redundantly in the LIN-12 and GLP-1/Notch pathways (Westlund et al., 1999). Similarly, mice
carrying a null mutation in PSEN1 showed embryonic lethality, skeletal defects, and disrupted
somite boundaries (Shen et al., 1997), similar to the phenotypes seen in Notch1 knockouts
(Duarte et al., 2004; Gale et al., 2004; Krebs et al., 2000, 2003, 2004).
In screening for novel mutants showing the glp-1/Notch phenotype of defective anterior
pharynx, Goutte and co-workers identified two genes, aph-1 and aph-2, which encodes the C.
elegans NCT ortholog (Goutte et al., 2000, 2002). Independently, Francis and co-workers
(Francis et al., 2002) screened for enhancers of sel-12/PSEN activity and identified pen-2
(presenilin enhancer 2). aph-2/NCT, pen-2, and aph-1 are all required for proper Notch
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signaling. Human PSEN, NCT, Aph1α2, and Pen-2 were subsequently shown to physically
associate and cooperatively regulate the maturation of individual components to form a
proteolytically active γ-secretase complex (Kimberly et al., 2003).

1.3.2 Function of APP family
The APP family of proteins contains three members, APP, APLP1 and APLP2 (Sandbrink et
al., 1994; Slunt et al., 1994; Sprecher et al., 1993; Wasco et al., 1992, 1992), which are
characterized by a large extracellular region containing conserved E1 and E2 domains, a single
transmembrane domain, and small, very well-conserved intracellular domain (Kang et al., 1987).
APLP1 and APLP2 do not contain the Aβ sequence and, hence, do not produce Aβ (Fig. 1A)
(Wasco et al., 1992, 1993). In rodents, APP and APLP2 are expressed in multiple tissue types
including the nervous system (Caldwell et al., 2013; Klevanski et al., 2014; Lorent et al., 1995;
Sarasa et al., 2000; Slunt et al., 1994; Wang et al., 2005), whereas APLP1 expression is restricted
to neurons (Lorent et al., 1995). The APP gene family is required for viability and brain
development. APP mouse knockouts were viable, but had behavioral and cognitive defects
(Ring et al., 2007). While knockout of APLP1 resulted in postnatal growth defects (Heber et al.,
2000), mice in which APLP2 was inactivated appeared wild type (von Koch et al., 1997).
Double knockouts of APLP2 and either APP or APLP1, however, resulted in postnatal lethality
(Heber et al., 2000; von Koch et al., 1997); the lethality of APP/APLP2 double knockouts could
be rescued by knock-in of sAPPα (Weyer et al., 2011), suggesting that sAPPα is sufficient for
viability. The triple knockout caused lethality and a type II lissencephaly and cortical
disorganization (Herms et al., 2004). Collectively, these results suggest that APP family
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members have essential and redundant functions during development, including proper brain
development, and these functions do not require Aβ.
One role of the APP family/APL-1 may also be to function as cell surface receptors and
provide a role in axon guidance. In wild type, APP-/-, and APLP2-/- single mutant mice, axons in
the corpus callosum appear to successfully cross the midline, connecting the left and right brain
hemispheres, whereas in APP-/-/APLP2-/- double knockouts, corpus callosum axons failed to
cross the midline (Wang et al., 2017). Similar defects were observed in Slit/Robo (LópezBendito et al., 2007; Unni et al., 2012) and Netrin/DCC defective mice (Fazeli et al., 1997;
Serafini et al., 1996), suggesting a link between both pathways and APP/APL-1.
Similar to wild-type olfactory bulb (OB) explants, APP and APLP2 single mutant
explants were repelled from Slit2-expressing cells. Conversely, APP-/-/APLP2-/- double mutant
OB explants failed to recognize Slit2 repellent cues (Wang et al., 2017). Importantly, APP
domain analysis and biochemical experiments demonstrated that APP E1 domain binds the Nterminus of Slit, while APP intracellular domain complexes with Robo (Wang et al., 2017).
APP-Slit interaction increases APP cleavage by ADAM10 to produce αAPP and increases
intracellular APP to complex with Fe65 and Pak1 (Wang et al., 2017), a key molecule in
cytoskeletal rearrangement (Bokoch, 2003). Pak1 interacts with the Nck family of adaptor
proteins, which have been shown to interact with guidance receptors, including Robo (Fan et al.,
2003) and DCC (Fan et al., 2003).
Similarly, in C. elegans, apl-1 RNAi knock down results in misguided ALM neurons in
approximately 30% of treated animals, comparable to ROBO/sax-3 RNAi treatment (Wang et
al., 2017). Furthermore, in sax-3(ky200) or slt-1(eh15) loss of function mutant backgrounds, apl1 knockdown did not further enhance ALM axon guidance defects (Wang et al., 2017),
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suggesting that apl-1 functions in the same pathway as Slit/Robo/SAX-3/SLT-1 in repulsive
axon guidance. In addition, apl-1 RNAi knockdown in unc-6(ev400) and unc-40(n324)
significantly enhanced the ALM axon guidance defect (Wang et al., 2017), suggesting that apl-1
and unc-6/unc-40 function in parallel pathways.

FIGURE 1. Similarities and differences between human APP and C. elegans APL-1. (A)
Schematic representation of human APP isoforms, other members of the APP family (APLP1
and APLP2), and C. elegans APL-1.
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(B) Comparison between human APP proteolytic pathways (top panel) and C. elegans APL-1
proteolytic pathway (bottom panel). Top panel. APP can be cleaved by two different pathways.
In the anti-amyloidogenic pathway, APP is first cleaved by the α-secretase to release an
extracellular fragment sAPPα. The remaining APP fragment (APP-CTFα or C83) is then
cleaved by the γ-secretase complex to release the APP intracellular domain (AICD) to the
cytosol. In the amyloidogenic pathway, β-secretase first cleaves APP, releasing the sAPPβ
fragment. The APP-CTFβ (C99) fragment is subsequently cleaved by the γ-secretase complex,
liberating the AICD to the cytosol and Aβ to the lumen. Aβ will aggregate to form amyloid
plaques. Bottom panel. In C. elegans, APL-1 is first cleaved by the α-secretase homologues
SUP-17/ADM-4, liberating the extracellular sAPL-1 whose activity regulates worm viability and
development. The γ-secretase complex then cleaves the remaining APL-1-CTF to release AICD
into the cytosol.

1.3.3 Function and regulation of APL-1
Like the mammalian APP family (Lorent et al., 1995; Slunt et al., 1994; Thinakaran et
al., 1995), apl-1 is expressed in multiple tissue types. APL-1 expression is observed in neurons,
supporting cells, and head muscles throughout development, while expression in vulval muscles,
vulval cells, and hypodermal seam cells is not detected until the L4 to adult stages (Hornsten et
al., 2007; Niwa et al., 2008).
Inactivation of apl-1 results in a completely penetrant lethality during the first to second
larval (L1 to L2) transition due to molting and morphogenetic defects (Hornsten et al., 2007).
apl-1 activity is also necessary for later larval transitions, as RNAi knockdown of apl-1 in an
RNAi-sensitized background showed animals with molting defects during every transition
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(Ewald et al., 2012a; Wiese et al., 2010). Hence, similar to the mammalian APP family, apl-1
has an essential function. High levels of apl-1 expression caused an incompletely penetrant L1
lethality (70% lethality), shortened body length, and morphogenetic, reproductive, and
locomotory defects (Ewald et al., 2012b; Hornsten et al., 2007). These results indicate that levels
of APL-1 must be tightly regulated as loss of APL-1 as well as high levels of APL-1 result in
lethality. When sel-12/PSEN activity was reduced in transgenic animals with APL-1
overexpression, the 70% lethality was partially rescued, suggesting that sel-12/PSEN regulates
APL-1 cleavage and/or trafficking (Hornsten et al., 2007). The underlying basis of the loss- and
gain-of-function apl-1 lethality is still unclear, but is not dependent on activation of caspase or
necrotic cell death pathways (Hornsten et al., 2007). Characterization of apl-1 function may
provide insights into the general function and pathways of APP, much of which is still unknown.
The apl-1(yn5) mutant, which contains a deletion of the region encoding the APL-1
transmembrane and cytosolic domains, produces only the extracellular domain of APL-1 (APL1EXT) and is viable. Because APL-1EXT is not further cleaved by α-secretase, APL-1EXT is
slightly larger than sAPL-1 and is present at high levels in apl-1(yn5) mutants (Hornsten et al.,
2007). Hence, the APL-1 extracellular domain is sufficient for viability, similar to the rescue of
APP/APLP2 double mutants by the knock-in of sAPPα (Weyer et al., 2011). However, although
apl-1(yn5) mutants are viable, they display several phenotypes, including a slower
developmental progression, decreased body length, reproductive defects, and temperaturesensitive lethality (Ewald et al., 2012b; Hornsten et al., 2007). Because these defects can be
phenocopied by microinjection of APL-1EXT transgenes into wild-type animals, the phenotypes
are due to overexpression of APL-1EXT and not due to loss of APL-1 signaling through its
cytoplasmic domain (Ewald et al., 2012b). Interestingly, pan-neuronal expression of APL-
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1EXT, but not expression from muscle or hypodermal cells, is sufficient to rescue the lethality
observed in apl-1 null mutants (Hornsten et al., 2007), suggesting that the cells (i.e., neurons)
from which sAPL-1 is released as well as the extracellular milieu in which sAPL-1 travels is
functionally relevant. We suggest that high levels of sAPP may also contribute to the pathology
seen in AD patients. Down’s syndrome patients, whose chromosome 21 trisomy includes
trisomy of APP, display a high incidence of Alzheimer’s disease and intellectual disability
(Zigman, 2013), perhaps contributed in small part by the high levels of APP expression.
Decreasing apl-1 activity by RNAi resulted in hypersensitivity to aldicarb, an
acetylcholinesterase inhibitor (Wiese et al., 2010). In apl-1 knockouts, high levels of full-length
APL-1 expression rescued, while transgenes lacking the AICD or the cytoplasmic YENPTY
sequence showed partial rescue of the aldicarb hypersensitivity phenotype (Wiese et al., 2010),
suggesting that lack of sAPL-1 is responsible for the aldicarb hypersensitivity. These findings
are consistent with mammalian studies, which show that a lack of APP and APLP2 impairs
synaptic function at cholinergic neuromuscular junctions (Wang et al., 2005).
Heterochronic genes, whose differential spatiotemporal expression ensures proper
progression through larval stages and transition into adulthood (Ambros and Horvitz, 1984;
Chalfie and Sulston, 1981), regulate expression of apl-1 in hypodermal seam cells (Niwa et al.,
2008). Loss of let-7 microRNA (miRNA) function caused precocious seam cell development
and vulval bursting at the adult stage, leading to death (Reinhart et al., 2000). These let-7
phenotypes can be rescued by knockdown of apl-1 (Niwa et al., 2008). apl-1, however, is not a
direct target of let-7 miRNA. NHR-25/Ftz-F1 binds an enhancer element in the promoter of apl1 to regulate apl-1 expression in seam cells (Niwa and Hada, 2010). In hbl-1, lin-41, and lin-42
heterochronic mutants, apl-1 expression was observed precociously at the L3 molt in seam cells,
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while normal apl-1 expression during late L4 was significantly reduced (Niwa et al., 2008); nhr25 RNAi in hbl-1, lin-41, lin-42 mutant backgrounds suppressed the precocious apl-1 expression
in L3 (Hada et al., 2010), suggesting that the regulation of apl-1 expression in seam cells is by
nhr-25/Ftz-F1. Regulation of continued apl-1 expression in adult seam cells and other cell types
is unknown.

1.3.4 Pathways through which apl-1 functions
The apl-1(yn5) phenotypes require activity of the DAF-16/FOXO transcription factor, which
is negatively regulated by the insulin pathway. C. elegans has only one insulin/IGF-1 receptor
ortholog, DAF-2 (Kimura et al., 1997). Under favorable environmental conditions, such as when
adequate food is present, signaling through the insulin pathway activates a conserved PI 3kinase/AKT cascade (Kimura et al., 1997; Morris et al., 1996), which causes phosphorylation of
DAF-16/FOXO, thereby allowing reproductive development (Gems et al., 1998; Henderson and
Johnson, 2001; Larsen et al., 1995). Phosphorylation of DAF-16/FOXO causes its sequestration
in the cytoplasm (Lin et al., 2001), thereby preventing it from entering the nucleus to activate its
target genes (Henderson and Johnson, 2001; Lee et al., 2001), which regulate longevity (Lin et
al., 1997; Ogg et al., 1997), stress resistance (McElwee et al., 2003, 2004; Murphy et al., 2003),
and dauer formation (Riddle et al., 1981; Vowels and Thomas, 1992). Environmental conditions
also affect other metabolic functions, such as reproductive behavior, which is inhibited under
starvation conditions (Seidel and Kimble, 2011), and body size. Starvation survival behavior is
regulated by DAF-16/FOXO activity (Lee and Ashrafi, 2008) and the insulin (So et al., 2011)
and daf-7 TGFβ (Savage-Dunn et al., 2003) pathways work in parallel to regulate body length
via daf-16/FOXO activity.
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The slowed development, decreased body size, and decreased reproductive rates of apl1(yn5) mutants are dependent on daf-16/FOXO activity. At 20oC, mutants with decreased
insulin signaling or apl-1(yn5) mutants showed a delayed developmental progression and shorter
body length, which were enhanced when insulin signaling was decreased in apl-1(yn5) mutants
(i.e., daf-2(e1370); apl-1(yn5) double mutants); at 25oC, the apl-1(yn5) mutants with decreased
insulin signaling went into L1 arrest (Ewald et al., 2012b). By contrast, when daf-16/FOXO
activity was removed from apl-1(yn5) mutants, the delayed developmental progression,
decreased reproductive rate, and smaller body length of apl-1(yn5) single mutants were
suppressed. Furthermore, loss of daf-16/FOXO activity in apl-1(yn5) mutants with decreased
insulin signaling suppressed the short body length and L1 arrest phenotypes (Ewald et al.,
2012b). These results suggest that sAPL-1 signals in a parallel pathway to the insulin pathway
or modulates the DAF-2/insulin/IGF-1 pathway to activate daf-16/FOXO activity to affect
developmental progression, reproductive rates, and body length. Mammalian sAPP may have
similar roles in development.
Activity of the daf-12 nuclear hormone receptor (NHR) signals in multiple pathways to
integrate environmental stimuli with metabolic needs and can modulate the insulin pathway as
well as function in an independent pathway (Dumas et al., 2010; Gerisch et al., 2001).
Decreasing daf-12/NHR activity in apl-1(yn5) mutants suppressed the slow development, low
reproductive rate, and decreased body length phenotypes (Ewald et al., 2012b). Hence,
decreased insulin signaling and signaling through a parallel daf-12/NHR pathway converge to
activate daf-16/FOXO for the phenotypes seen in apl-1(yn5) mutants. Noteworthy, levels of
insulin/IGF-1 receptors are decreased in AD brains (Steen et al., 2005), and APP processing and
Aβ production in vitro was modulated by insulin signaling (Gasparini et al., 2001). Analogous to
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C. elegans, sAPP also may act to modulate the insulin pathway.

1.3.5 Pan-neuronal APL-1 expression affects learning
In transgenic mice expressing human or mouse APP, animals showed an increased lethality
and learning defects that were not correlated with Aβ deposition (Hsiao et al., 1995); similarly,
doubly transgenic mice carrying transgenes with APP and PSEN1 mutations showed learning
defects that were not correlated with the number of Aβ plaques (Holcomb et al., 1999). The
mechanisms underlying these defects are unclear. Use of the C. elegans model could be
informative. C. elegans has many sensory modalities, including smell and taste. They respond to
volatile and water soluble chemicals by moving towards or away from chemoattractive or
chemorepulsive stimuli, respectively. Many chemoattractants and chemorepellants have been
identified and the neural circuits mediating the chemosensory response identified (Bargmann and
Horvitz, 1991). For instance, when C. elegans is given the choice between a neutral compound
and a chemoattractant, such as benzaldehyde, animals will move towards benzaldehyde; this
response is mediated by the AWC neurons (Bargmann et al., 1993); similarly, ASEL, a gustatory
neuron, mediates chemoattraction to sodium acetate (Bargmann and Horvitz, 1991; PierceShimomura et al., 2001).
Although apl-1 is not expressed in AWC neurons and the morphology of sensory neurons
appears wild type with GFP markers, the overall chemoattractive response to benzaldyhyde and
sodium acetate was decreased in apl-1(yn10/+) heterozygotes and transgenic animals that
overexpress APL-1 (e.g., ynIs79 [Papl-1::apl-1::GFP]) (Ewald et al., 2012a). The chemotaxis
response was restored in APL-1 overexpression lines (e.g., ynIs79 [Papl-1::apl-1::GFP]) when
insulin signaling was decreased, but not when daf-16/FOXO activity was decreased, suggesting
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that daf-16/FOXO activity is needed for normal chemotaxis in transgenic lines overexpressing
APL-1 (Fig. 2). Pan-neuronal expression of APL-1 or targeted overexpression of APL-1 in the
AWC or ASEL neurons resulted in wild-type chemotaxis responses (Ewald et al., 2012a). By
contrast, ectopic expression of apl-1 with the snb-1 promoter, which drives pan-neuronal and
multi-cell type expression, resulted in no chemotaxis response to benzaldehyde or sodium acetate
(Ewald et al., 2012a). When signaling through daf-2/insulin/IGF-1 receptor, daf-12/NHR, or
daf-7/TGFβ was decreased, the chemotaxis response towards benzaldehyde and sodium acetate
in these transgenic lines was restored (Fig. 2), indicating that the loss of the chemotaxis response
due to ectopic apl-1 signaling in cells outside the nervous system is dependent on insulin and
TGFβ signaling.
In addition to chemosensory responses, C. elegans is also capable of associative
chemosensory plasticity (Wen et al., 1997). For example, when benzaldehyde was paired with
starvation for as short as 30 minutes, C. elegans showed a significant reduction in preference for
benzaldehyde; persistence of this plasticity was positively correlated with the length of pairing
time (Colbert and Bargmann, 1995; Lin et al., 2010; Tomioka et al., 2006), suggestive of stable
memory formation. Both chemotaxis and associative plasticity are dependent on insulin
signaling (Lin et al., 2010; Tomioka et al., 2006). Little associative plasticity, however, was
observed after pairing benzaldehyde with starvation for 60 minutes in animals with pan-neuronal
APL-1 expression (Ewald et al., 2012a). The plasticity could be restored when daf-16/FOXO,
daf-12/NHR, or daf-7/TGFβ activity was decreased, indicating that the impaired associative
plasticity with pan-neuronal APL-1 expression requires daf-16/FOXO, daf-12/NHR, and daf7/TGFβ activity (Ewald et al., 2012a).
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Touch habituation is another sensory characteristic affected by pan-neuronal APL-1
expression. When a gentle touch is applied to the head of the animal, C. elegans responds by
moving backwards; conversely, when touched on the tail, the animal moves forward (Chalfie and
Sulston, 1981). This response to gentle body touch is mediated by six mechanosensory touch
neurons (Chalfie et al., 1985). After six cycles of alternating head/tail touches, wild-type
animals habituated and became unresponsive (Ewald et al., 2012a). apl-1(yn10/+) heterozygotes
or transgenic animals that overexpress APL-1 showed touch habituation. By contrast, animals
with pan-neuronal APL-1 expression were slow to habituate and required more alternating
head/tail touch cycles before becoming habituated (Ewald et al., 2012a). Collectively, these
results indicate that pan-neuronal overexpression of APL-1 causes learning defects. These
results parallel those seen in mammalian models in which overexpression of APP leads to
cognitive defects, independent of Aβ aggregates (Hsiao et al., 1995; Simón et al., 2009), thereby
suggesting that sAPP activity, in addition to Aβ aggregates, contributes to cognitive defects.
Whether these cognitive defects depend on the DAF-16/FOXO transcription factor and/or TGFβ
signaling remains to be tested.
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FIGURE 2. Interaction between sAPL-1 and insulin/daf-2 and daf-12/NHR pathways.
Schematic representation of APL-1 proteolytic pathway and how sAPL-1 may modulate
insulin/DAF-2 and DAF-12/NHR signaling pathways. APL-1 is cleaved by the α/γ-secretase
pathway in C. elegans. Released sAPL-1 could act as a signaling molecule in the same cell
(autocrine regulation) or in neighboring cells (paracrine regulation) to inhibit daf-2 insulin/IGF-1
receptor and daf-12/NHR pathways to affect worm viability and development. The exact
mechanism by which sAPL-1inhibits daf-2 insulin/IGF-1 receptor and daf-12/NHR is still
unknown and labeled as a question mark (see Ewald et al., 2012b).

1.3.6 APL-1 trafficking is important for synaptic transmission

18

APL-1, like APP (Koo et al., 1990), is transported from the cell body to synapses (Wiese et
al., 2010). UNC-108, which is a neuronally expressed GTPase and localizes to the Golgi
complex and early endosomes (Edwards et al., 2009; Mangahas et al., 2008), is involved in the
maturation of dense core vesicles (Borgonovo et al., 2006; Edwards et al., 2009; Mangahas et al.,
2008; Sumakovic et al., 2009), of which APL-1 is one of the contents. APL-1 co-localizes with
vesicles that contain UNC-108 GTPase. When unc-108 GTPase activity is decreased, there is an
accumulation of APL-1 in cell bodies and no APL-1 expression in axons (Wiese et al., 2010),
suggesting a disruption in APL-1 packaging into mature dense core vesicles and a lack of
anterograde APL-1 transport. Both UNC-116/kinesin-1 and UNC-104/KIF1A/kinesin-3 are
involved in the anterograde transport of APL-1 (Arimoto et al., 2011; Wiese et al., 2010), but
only UNC-116/kinesin-1 and dynein motors are responsible for the retrograde transport of APL1 back to the cell body (Arimoto et al., 2011). The rates of anterograde and retrograde transport
of APL-1 vesicles are 1.1 µm/s and 1.6 µm/s, respectively (Arimoto et al., 2011). Hence, APL-1
is transported similarly as in mammalian models where kinesin-1 is responsible for APP axonal
transport (Koo et al., 1990). Surprisingly, mutations in unc-116/kinesin-1 and unc104/KIF1A/kinesin-3 both caused decreased levels of APL-1 expression without affecting
transcript levels, suggesting that without transport motors, APL-1 does not accumulate in cell
bodies because of protein degradation (Arimoto et al., 2011; Wiese et al., 2010).
APL-1 is also internalized from the cell surface of neurons. APL-1 co-localizes with RAB-5
(Wiese et al., 2010), the C. elegans ortholog of mammalian RAB5, which is expressed in early
endosomes where it regulates endocytosis (Bucci et al., 1992; Grant and Hirsh, 1999). Loss of
rab-5 results in a decrease in APL-1::GFP levels in neuronal cell bodies and an absence of APL1 in axons. These data suggest that APL-1 is internalized via RAB-5-dependent endocytosis.

19

1.3.7 Hypodermal APL-1 expression increases lifespan
APL-1 activity impacts longevity in a context-specific manner. Ubiquitous expression of
APL-1 using the hsp-16.1 promoter increases longevity, while overexpressing apl-1 under the
control of its endogenous promoter decreases lifespan (Ewald et al., 2016). When APL-1 is
overexpressed either pan-neuronally (using the rab-3 promoter) or in subsets of neurons (using
the ceh-36 promoter, which drives expression in chemosensory neurons, or the mec-4 promoter,
which drives expression in mechanosensory neurons), lifespan is decreased (Ewald et al., 2016).
Conversely, apl-1 or APL-1EXT overexpression driven by the snb-1 promoter, which causes
APL-1 or APL-1EXT to be expressed in neurons, somatic gonad and hypodermal cells, enhances
longevity; furthermore, apl-1 or APL-1EXT overexpression in hypodermal cells using the col-10
promoter is sufficient to increase lifespan (Ewald et al., 2016).
Altogether, these data suggest that increased expression of apl-1 from neurons leads to a
decrease in longevity, whereas apl-1 or APL-1EXT expression from hypodermal cells is
sufficient to increase longevity (Ewald et al., 2016). Additionally, APL-1 expression in the
hypodermis is sufficient to increase longevity while counteracting the decreased longevity due to
APL-1 expression in neurons. Because APL-1EXT expression in hypodermal cells is sufficient
to increase longevity (Ewald et al., 2016), this result indicates that AICD activity does not play a
role in lifespan extension. Paradoxically, although apl-1 activity in the hypodermis leads to
increased lifespan, neither full length APL-1 nor sAPL-1 expression in the hypodermis is able to
rescue the lethality due to loss of apl-1 (Ewald et al., 2016; Hornsten et al., 2007). Therefore, the
role of apl-1 in viability is independent of its role in longevity.
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DAF-16/FOXO, DAF-12/VDR, and HSF-1/heat-shock transcription factor ortholog
activities are necessary for the lifespan extension observed in mutants overexpressing APL-1 or
APL-1EXT in their hypodermis. Both DAF-16/FOXO, DAF-12 (Antebi, 2013; Kenyon, 2010),
and HSF-1 (Hsu et al., 2003) have been shown to trigger a cascade of gene activations, which
culminate in increased lifespan. daf-16 null mutations, daf-12 hypomorphic mutations, and hsf-1
RNAi, each coupled with hypodermal APL-1 or APL-1EXT overexpression, completely
eliminates the extended lifespan seen in APL-1 or APL-1EXT overexpression in hypodermal
cells (Ewald et al., 2016). Together, these data suggest that key members of longevity pathways,
daf-16, daf-12 and hsf-1, are required for APL-1-/APL-1EXT-mediated longevity.
lin-14 is a transcription factor that is responsible for the transition from the L1 to L2
larval stage (Hristova et al., 2005), a developmental transition that also requires apl-1 activity
(Hornsten et al., 2007). lin-14 RNAi knockdown and hypomorphic alleles are sufficient to
extend lifespan (Boehm and Slack, 2005). Coupling lin-14 RNAi knockdown or lin-14
hypomorphs with hypodermal apl-1 overexpression does not result in further lifespan extension,
suggesting that apl-1 and lin-14 act in the same pathway to regulate lifespan; however, coupling
lin-14 overexpression with apl-1 overexpression in the hypodermis leads to suppression of the
lifespan extension induced by apl-1 overexpression (Ewald et al., 2016). These data suggest that
in hypodermal cells, apl-1 represses lin-14 activity, thereby leading to lifespan extension.
Furthermore, genes whose activity is downregulated by lin-14 are upregulated when apl-1 is
overexpressed; genes whose activity is upregulated by lin-14 are downregulated when apl-1 is
overexpressed (Ewald et al., 2016).
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Overall, these findings reiterate the multiple functions of APL-1, which are spatially and
temporally specific: APL-1 expression from neurons is necessary and sufficient for viability,
whereas APL-1 expression from hypodermal cells impacts longevity.

1.3.8 AICD intracellular trafficking
The Fe65 family of proteins binds the cytoplasmic YENPTY sequence of APP, APLP1 and
APLP2, via their PTB2 domain (Duilio et al., 1998; Guénette et al., 1996; Russo et al., 1998;
Zambrano et al., 1997). Likewise, the sole family member ortholog in C. elegans, FEH-1, has a
WW domain and PTB1 and PTB2 domains, which closely resemble those of the Fe65 family,
and the PTB2 domain of FEH-1 interacts with APL-1 (Zambrano et al., 2002).
FEH-1 is expressed in pharyngeal muscle and neuronal processes and is necessary for
survival. Inactivation of feh-1 caused an incompletely penetrant embryonic lethality. Survivors
showed little pharyngeal pumping and were unable to feed, thereby resulting in L1 arrest
(Zambrano et al., 2002). Decreasing feh-1 activity or decreasing feh-1 dosage caused pharyngeal
pumping rates to increase, suggesting that the rate of pharyngeal pumping is feh-1 dosage
dependent. However, the functional significance of FEH-1 and APL-1 interactions is unclear as
apl-1(yn5) mutants, which do not have an AICD domain, and apl-1(yn10/+) heterozygotes do
not have defective pumping rates (Ewald et al., 2012b).

1.3.9 Investigating the amyloid hypothesis of AD in C. elegans
Aβ peptide, the cleavage product of APP believed to underlie the pathology of AD (Glenner
and Wong, 1984; Gorevic et al., 1986; Masters et al., 1985; Selkoe et al., 1986), is not present in
APL-1 (Daigle and Li, 1993), nor does C. elegans possess β-secretase activity to produce Aβ
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(Link, 2006). Nevertheless, C. elegans provides a powerful in vivo genetic system to study the
effects of neurotoxic Aβ through transgene analysis (Shankar et al., 2008). Many transgenic
strains have been generated in which a signal sequence followed by the human Aβ sequence is
expressed in all cells, in all neurons, in specific subsets of neurons, or in muscle cells. These
strains produce either Aβ1-42 or Aβ3-42.
AD is a late onset neurodegenerative disease. C. elegans expressing human Aβ3-42 in muscle
tissue (Link, 1995; Link et al., 2001) showed an age-dependent paralysis at 20oC (Cohen et al.,
2006; McColl et al., 2009); paralysis occurred more rapidly and more severely when Aβ1-42 was
produced at 25oC (McColl et al., 2009). The level of muscle paralysis was significantly
decreased when insulin signaling was decreased (Cohen et al., 2006). Furthermore, inhibiting
daf-16 FOXO and hsf-1, which encodes a heat shock protein transcription factor (Hsu et al.,
2003; Morley and Morimoto, 2004), reversed the effects of decreased insulin signaling (Cohen et
al., 2006). Hence, the paralysis effects of Aβ correlates with age and is dependent on insulin
signaling.
Since aggregated Aβ is toxic to neurons (Glenner and Wong, 1984; Gorevic et al., 1986;
Masters et al., 1985; Selkoe et al., 1986) and causes muscle paralysis in C. elegans, molecules
and pathways that can prevent the formation or promote the disassembly of Aβ aggregates can be
screened for in C. elegans. For instance, when C. elegans extracts are incubated with aggregated
human Aβ3-42 in the presence or absence of protease inhibitors, disaggregation occurred, but
disaggregation did not occur when extracts were either heated to denature proteins or incubated
with proteinases (Bieschke et al., 2009). Hence, an unidentified protein or protein complex in C.
elegans extracts can disaggregate Aβ3-42 aggregates.
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Several orthologues to human heat shock (HSP) chaperone proteins were found to interact
directly with Aβ3-42 in C. elegans. C. elegans HSP-16 proteins, HSP-16-1, HSP-16-2 and HSP16-48, orthologues of αB-crystallin, bound intracellular Aβ3-42 monomers and soluble Aβ3-42
oligomers, but not fibrillar Aβ3-42 (Fonte et al., 2002). Moreover, hsp-16 transcript levels were
upregulated in Aβ3-42 transgenic lines, but whether these chaperone proteins protect against or
promote Aβ paralysis is unclear (Fonte et al., 2002). By contrast, increased expression of the
HSP70 chaperones had a protective role by suppressing paralysis (Fonte et al., 2008). These
results are consistent with human studies showing that HSP70 and αB-crystallin were
upregulated in AD brains (Hamos et al., 1991; Perez et al., 1991; Renkawek et al., 1994;
Shinohara et al., 1993; Yoo et al., 2001) and binds Aβ (Liang, 2000).
Transgenic C. elegans lines in which Aβ is expressed in glutamatergic neurons showed agedependent neurodegeneration, whereby 7-day adults showed 75% glutamatergic
neurodegeneration (Treusch et al., 2011). This degeneration was suppressed when genes
involved in clathrin-mediated endocytosis, such as unc-11, unc-26, Y44E3A.4, C. elegans RTS1
ortholog, C. elegans ADE12 ortholog, and human CRMI, were co-expressed with Aβ, and
enhanced when a PBS2/MAP2K4 mitogen-activated protein kinase was co-expressed with Aβ in
glutamatergic neurons (Treusch et al., 2011). Interestingly, mutations in the C. elegans human
REST ortholog spr-4, which suppressed the sel-12/PSEN egg-laying defect (Lakowski et al.,
2003), also enhanced the degeneration seen in the transgenic animals expressing Aβ in
glutamatergic neurons (Lu et al., 2014). Modifying clathrin-mediated endocytosis in rat cortical
neurons was similarly neuroprotective against Aβ aggregates (Treusch et al., 2011). In addition,
early stage AD brains showed higher expression of REST target genes, while late stage AD and
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frontotemporal dementia brains showed lower expression (Lu et al., 2014). Hence, REST may
confer neuroprotective benefits in C. elegans and in humans (Lu et al., 2014).
The C. elegans Aβ model also proves useful in screens to identify drugs that disaggregate
Aβ. The drug PBT2, an 8-hydroxy quinoline analog, reversed AD phenotypes in mice within
days (Adlard et al., 2008). Similarly, C. elegans expressing inducible Aβ1-42, which become
paralyzed within 48 hrs after induction, were protected against paralysis when exposed to PBT2
(McColl et al., 2012).
Although C. elegans does not generate Aβ, C. elegans remains an excellent model to
study the effects of Aβ accumulation during AD pathogenesis. Weighted Gene Co-expression
Network Analysis (WGCNA) and Protein-Protein Interaction Network (PPI) approaches were
used to identify Aβ-interacting genes when Aβ1-42 expression is driven in C. elegans muscles and
neurons. The genes identified in C. elegans had orthologs in humans whose expression levels
were confirmed to be perturbed during AD progression (Godini et al., 2019).
To further investigate Aβ in C. elegans and the implications for AD, single copies of Aβ1-42
were inserted into the C. elegans genome, under a flp-17 promoter driving intracellular
expression in a pair of BAG neurons (Sinnige et al., 2019). BAG neurons are glutamatergic,
similar to those most susceptible neurons to AD in humans (Esposito et al., 2013; Francis, 2003;
Revett et al., 2013). BAG neurons are activated in response to CO2 and hypoxia (Bretscher et al.,
2008; Fenk and de Bono, 2015; Hallem and Sternberg, 2008; Hallem et al., 2011). Unlike other
Aβ C. elegans models (Dosanjh et al., 2010; McColl et al., 2012), no Aβ1-42-related toxicities
and paralysis were evident. Upon exposure to CO2, BAG-Aβ1-42 transgenic animals did not show
characteristic omega turns like wild-type. Furthermore, only soluble Aβ1-42 was found in C.
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elegans. Overall, the phenotypes using the BAG-Aβ1-42 are subtle, hinting at its potential to
study the initial stages of AD.

1.3.10 C. elegans lrp-1 functions similarly to LRP2/megalin, an LDL receptor family
member
In mammals, the LDL receptor family is responsible for many functions, including binding
ligands for internalization and degradation and cholesterol metabolism (Brown and Goldstein,
1986; Herz et al., 1992; Mahley, 1988; Willnow et al., 1994). Binding of LRP1 to sAPP770 or
full-length APP770 causes its internalization and degradation (Knauer et al., 1996; Kounnas et
al., 1995); disrupting cell surface APP internalization with an LRP-antagonist increases sAPPα
processing and full-length APP at the cell surface and decreases Aβ formation, suggesting that
LRP1-APP interactions favor APP processing through the amyloidogenic pathway (Ulery et al.,
2000). Apolipoprotein E (APOE) and LRP2/megalin have also been implicated in Aβ clearance
(Carro et al., 2005; Deane et al., 2004; Zlokovic et al., 1996).
Different alleles of the APOE gene are correlated with AD. APOE has three common
alleles: APOE2, which is associated with lower risk of late-onset AD, APOE3, which is AD
neutral, and APOE4, which is associated with late-onset AD (Corder et al., 1993). A rare
recessive mutation in APOE3, APOE3ch, was discovered to be protective against the PSEN1E280A mutation associated with early-onset AD (Arboleda-Velasquez et al., 2019). In spite of
having the PSEN1 E280A mutation, a woman with the APOE3ch allele survived into her 70s.
PET analysis showed that she had unusually higher levels of Aβ1-42 plaque accumulation than her
PSEN1 E280A counterparts in their 40s. Interestingly, tau tangles and neurodegeneration were
relatively low, sparing brain regions that are characteristically AD-prone (Arboleda-Velasquez et
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al., 2019). In vitro Aβ1-42 aggregation analysis revealed that in the presence of APOE3ch, Aβ1-42
fragments were significantly less likely to aggregate than when in the presence of APOE3.
APOE3ch comprises a R136S mutation (Arboleda-Velasquez et al., 2019) in a region that
is critical for lipoprotein receptor and heparan sulfate proteoglycan (HSPG) binding (ArboledaVelasquez et al., 2019; Lalazar et al., 1988; Mahley et al., 1999). HSPG-APOE interactions may
promote Aβ1-42 aggregation and neuronal uptake of extracellular tau (Rauch et al., 2018).
Binding assays showed that APOE3ch, compared to other APOE alleles, had the lowest HSPG
binding affinity (Yamauchi et al., 2008). Furthermore, synthetic molecules that bind amino acids
130 to 143 (which includes R136S) of APOE3, reduced APOE3-heparin binding to levels
comparable to APOE3ch-HSPG (Arboleda-Velasquez et al., 2019). Altogether, these data
suggest a protective role for APOE3ch due to its altered affinity for HSPG and its effects on tau
pathology, thereby modifying the development of AD.
C. elegans LRP-1 most closely resembles mammalian LRP2/megalin (Yochem and
Greenwald, 1993; Yochem et al., 1999). C. elegans does not have the ability to synthesize
cholesterol and, therefore, must rely on dietary sources (Hieb and Rothstein, 1968). Inactivation
of lrp-1 resulted in late larval lethality due to molting defects during the L3 to L4 transition
(Yochem et al., 1999). When wild-type C. elegans were grown in the absence of cholesterol, the
molting defects of the lrp-1 knockouts were phenocopied (Wiese et al., 2012; Yochem et al.,
1998), suggesting that LRP-1 is involved in cholesterol uptake from the environment. LRP-1 is
expressed in the epithelial hypodermal cells, hyp6 and hyp7, where it localizes to their apical
surface (Yochem et al., 1999) and where apl-1 is also expressed in adults (Niwa et al., 2008).
Similarly, its mammalian counterpart, LRP2/megalin, is mainly expressed at the apical surface of
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epithelial cells (Cui et al., 1996; Hermo et al., 1999; Mizuta et al., 1999; Morales et al., 1996;
Nielsen et al., 1998; Willnow et al., 1996; Zheng et al., 1998).
LRP2/megalin interacts with different domains of APP (Cam and Bu, 2006; Carro et al.,
2005; Pietrzik et al., 2004; Yoon et al., 2005; Zlokovic et al., 1996). A physical interaction
between APL-1 and LRP-1 has not been determined. A constitutively activated LRP-1 did not
suppress the lethality of apl-1 null mutants, suggesting that sAPL-1 is not activating an lrp-1
pathway (Hornsten et al., 2007). When lrp-1 expression is decreased or when wild-type animals
are deprived of dietary cholesterol, neurotransmission is affected (Wiese et al., 2012). However,
apl-1 null mutants die at an earlier stage in development than lrp-1 null mutants, suggesting that
apl-1 functions in earlier developmental pathways that are necessary for survival.

1.4 tau/PTL-1 in AD
Accumulation of neurofibrillary tangles in cell bodies is another hallmark characteristic of
AD and other neurodegenerative disorders. The major component of these tangles is tau, which
belongs to the family of microtubule-associated proteins (MAPs) that includes MAP2 and MAP4
(Chapin and Bulinski, 1991; Goedert et al., 1989b; Lee et al., 1988; Lewis et al., 1988). MAPs
share characteristic homology domains, including a proline-rich domain and a region of a
variable number of tandem amino acid repeats (Fig. 3) (Aizawa et al., 1990; Goedert et al., 1988,
1989b, 1989a, 1992a; Lee et al., 1988; Lewis et al., 1988). Tau is the predominant MAP
expressed in axons, while MAP2 is expressed in dendrites (Binder et al., 1985; Matus et al.,
1981) and MAP4 is expressed in dividing cells (Bulinski and Borisy, 1980). MAPs bind
microtubules and are responsible for promoting microtubule assembly and stability (reviewed in
Amos and Schlieper, 2005). MAP family members appear to have redundant functions; mice in
which tau was knocked out were viable, but showed increased levels of MAP1A (Harada et al.,
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1994), suggesting that upregulation of MAP1A can compensate for the lack of tau in vivo. Tau
phosphorylation affects its ability to bind microtubules and can cause a conformational change
that favors tubulin assembly (Feijoo et al., 2005). Aberrant hyperphosphorylation of tau,
however, impairs its ability to bind microtubules, thus resulting in their disassembly (Biernat et
al., 1993; Bramblett et al., 1993; Lindwall and Cole, 1984). In addition, phosphorylated tau selfaggregates into paired helical filaments (PHFs) and presumably generates the intracellular
neurofibrillary tangles characteristic of AD patients (Alonso et al., 2001, 1996, 1997; Billingsley
and Kincaid, 1997; Goedert et al., 1992b).
Because of the functional redundancy of MAPs, their specific functions have been difficult
to determine. C. elegans has only one tau ortholog PTL-1 (protein with tau-like repeats 1
(Goedert et al., 1996; McDermott et al., 1996). PTL-1 exists as two isoforms, PTL-1A and PTL1B, with five or four tandem repeats, respectively (Goedert et al., 1996) (Fig. 3A). They have a
high level of sequence homology with mammalian tau, especially in the C-terminal microtubule
binding region (Goedert et al., 1996; McDermott et al., 1996). Both PTL-1A and PTL-1B bind
microtubules in vitro and induce tubulin polymerization (Goedert et al., 1996; McDermott et al.,
1996). PTL-1 is initially expressed embryonically in the epidermis of elongating embryos and in
head neurons; in larval and adult animals PTL-1 is expressed mainly in the mechanosensory
neurons mediating gentle body touch (Goedert et al., 1996; Gordon et al., 2008), although
transcriptional fusions show a wider expression pattern that includes head and ventral cord
neurons, the tail interneurons DVA/B, which contribute to the mechanosensory neural circuitry
(de Bono and Maricq, 2005), and stomatointestinal cells (Gordon et al., 2008).
Loss of ptl-1/tau results in an incompletely penetrant lethality at the elongation stage of
embryogenesis (Gordon et al., 2008), which corresponds to the stage at which PTL-1/tau
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expression is first observed (Goedert et al., 1996). ptl-1/tau mutants that escaped lethality
showed normal development, but had a shortened lifespan, and although the overall integrity of
microtubule structure appeared unaffected at the light microscopic level, there was a significant
reduction in gentle touch sensitivity as compared to wild-type (Chew et al., 2013; Gordon et al.,
2008). These touch defects are enhanced in mutants with defects in β- and α-tubulin, indicating
that the absence of full-length PTL-1/tau disrupts mechanosensation, but it does so
independently of tubulin (Gordon et al., 2008). In mutants in which only the C-terminal
microtubule binding repeats of PTL-1/tau are deleted, touch sensitivity is identical to that of
wild-type (Chew et al., 2013), suggesting that the N-terminal domain of PTL-1/tau is sufficient
for gentle touch responses.
As C. elegans ages, mechanosensory touch neurons exhibit age-related morphological
changes: cell bodies initially elaborate branches and axons subsequently display blebbing and
branching (Pan et al., 2011; Tank et al., 2011; Toth et al., 2012). Strikingly, mechanosensory
touch neurons in ptl-1/tau mutants displayed these aging characteristics at higher incidences and
at an earlier stage than wild-type animals; GABAergic neurons also showed aging-related
phenotypes, such as ectopic branching (Chew et al., 2013). Expression of a human tau isoform
(htau40) in ptl-1/tau mutants rescued the touch insensitivity, but not the morphological aging
defects, indicating that htau40 shares some functional conservation with PTL-1/tau (Chew et al.,
2013). Interestingly, when ptl-1/tau is expressed in Sf9 cells, cells projected neurite-like
processes that were positive for PTL-1/tau immunoreactivity (Goedert et al., 1996) and that were
indistinguishable from those visualized when a htau40 is expressed in Sf9 cells (Chen et al.,
1992; Knops et al., 1991). Although wild-type PTL-1/tau has not been reported to aggregate into
fibrils, PTL-1/tau, like human tau, clearly has an essential role in maintaining neuronal integrity,
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controlling neuronal aging, and affecting lifespan (Goedert et al., 1996; Gordon et al., 2008).
While there are no known mutations in tau that are associated with AD, tau mutations are
associated with frontotemporal dementia with parkinsonism (FTPD-17), another form of
dementia (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998).

FIGURE 3. Similarities and differences between human tau and C. elegans ptl-1.
(A) Schematic representation of human microtubule binding proteins (MAPs) family, including
tau isoforms and C. elegans PTL-1 isoforms. (B) Comparison between tau functions in humans
(top panel) and C. elegans PTL-1/tau functions (bottom panel). Top panel. Tau has a
physiological role promoting and maintaining microtubule stability. In pathological conditions
tau is hyerphosphorylated and self-aggregates into paired helical filaments (PHFs) that can form
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intracellular neurofibrillary tangles (NFT). Bottom panel. C. elegans PTL-1/tau binds
microtubules and induces microtubule assembly. It also affects synaptic transport through motor
proteins UNC-104/KIF1a/kinesin-3, UNC-116/kinesin-1, and DLC-1/dynein. PTL-1/tau is also
important for C. elegans mechanosensation and aging.

1.5 Advantages and limitations of the C. elegans model
The use of C. elegans to study Alzheimer’s disease and other neurodegenerative diseases
has, as with many other models, many advantages as well as some drawbacks. Major advantages
of C. elegans include the ability to perform forward genetic, RNAi, and high throughput
chemical screens and the ease of generating transgenic lines. These benefits have been effective
in translating the necessity for sAPP, the role of APP and the presenilins, and identifying
components of the γ-secretase complex. The function of APP and the pathways in which it acts
are still unclear. C. elegans presents a complementary system in which these questions can be
addressed. Furthermore, overexpression of the APP ortholog APL-1 by mutation or by transgene
induces phenotypes that converge on the insulin/DAF-16/FOXO pathways, similar to what has
been found in mammals. Although APL-1 does not contain the Aβ sequence and C. elegans
does not have β-secretase activity, transgenic lines that produce Aβ expression pan-neuronally or
in muscle are being used to identify pathways that detoxify the Aβ aggregates, some of which
also involve the insulin/DAF-16/FOXO pathways. Whether these models are relevant to human
pathology or whether the pathways will be conserved in humans are unknown; however, they
present alternative approaches to understanding neurodegenerative diseases for which there are
currently few effective therapies. Human tau, as well as mutant tau isoforms, have also been
expressed in the worm to recapitulate AD and FTD phenotypes. Recent findings have shown
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that PTL-1 regulates neuronal aging in the worm. These findings may be important to link aging
and tau pathology in AD and FTD patients.
AD is considered a multifactorial disease in which other risk factors, such as
neuroinflammation, head trauma, and diabetes, may be important in the development of the
disease. The C. elegans nervous system is simple compared to the human nervous system. This
simplicity allows researchers to study neuronal function and neural circuits in a tractable system.
However, the complex network of connections and cell interactions found in humans is not
mimicked in C. elegans and this complexity may underlie some of the pathology of
neurodegenerative diseases. Nevertheless, most of the pathways and signaling molecules in C.
elegans are conserved between worms and mammals. The goal is to translate some of the C.
elegans insights into understanding the pathology of AD and other neurodegenerative diseases
and designing effective strategies to treat the diseases.
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II. 1 ABSTRACT
Familial Alzheimer’s disease is correlated with mutations in the amyloid precursor protein
(APP) gene and in genes that process APP. The biological functions of APP remain unclear.
APP is a single-pass transmembrane protein, which is cleaved to yield several fragments. A
family of APP proteins that have overlapping functions is present in mammals. Loss of the
APP family leads to lethality. Because of the difficulty of undertaking genetic screens in
mammals, we have turned to Caenorhabditis elegans, which encodes only one APP-related
protein, APL-1. Like the APP family, apl-1 knockouts show lethality, indicating that its
activity is essential for viability. To identify genes that act in the apl-1 pathway, we
performed genome-wide genetic screens for mutants that bypass the need for apl-1 activity.
We identified two mutants, whose mutations fell into one complementation group. The
mutants were examined for their developmental progression, fecundity, and lifespan.
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II.2 Article Summary
Mutations in several genes, including the amyloid precursor protein (APP) and enzymes that
cleave it, are correlated with inherited forms of Alzheimer’s disease. A family of APP genes is
present in mammals, where they have overlapping functions; however, loss of this family results
in postnatal lethality, indicating an essential function for the APP family. The normal function
of APP and its cleavage products remains unclear. Here, we use the nematode Caenorhabditis
elegans as a model to examine APP function. C. elegans contains one APP-like gene, which has
an essential function. We performed genetic screens to identify genes that act in the same
pathway as apl-1. Several mutants were isolated and characterized.
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II.3 INTRODUCTION
Alzheimer’s disease (AD) is the leading cause of dementia and the 6th leading cause of death
in the United States (Gaugler et al., 2019). One hallmark of the disease is the deposition in the
brain of extracellular senile plaques, which are comprised of aggregated Aβ peptides (Kidd,
1964; Krigman et al., 1965; Luse and Smith, 1964; Terry et al., 1964). Aβ is a cleavage product
of the amyloid precursor protein APP (Glenner and Wong, 1984; Kang et al., 1987; Masters et al.,
1985). Mutations in APP, which is located on chromosome 21, have been correlated with a
small number of familial AD cases (Cabrejo et al., 2006; Chartier-Harlin et al., 1991; Goate et al.,
1991; Murrell et al., 1991; Rovelet-Lecrux et al., 2006; Sleegers et al., 2006); furthermore,
Down’s syndrome patients, who have three copies of chromosome 21, show high incidences of
AD by the age of 60 (Zigman, 2013). Most mutations in FAD patients, however, are in the
presenilin genes, which encode proteases that cleave APP (Levy-Lahad et al., 1995; Rogaev et
al., 1995; Sherrington et al., 1995).
APP is a type I, single pass transmembrane domain protein (Kang et al., 1987), which is
processed by two major pathways. These pathways differ in their initial cleavage of APP, which
can be cleaved by either an α- or β-secretase to release a large extracellular fragment (sAPPα or
sAPPβ, respectively); the remaining fragment is subsequently cleaved by the γ-secretase to
release a small intracellular fragment (AICD) and, in the case of a previous β-secretase cleavage,
the β-amyloid peptide (reviewed in (Gralle and Ferreira, 2007). The biological functions of the
cleaved APP fragments, sAPPα/β and AICD, remain unclear, and elucidating the function of
APP is complicated by two APP paralogues, APLP1 and APLP2. Although APLP1 and APLP2
are very similar in sequence to APP, neither protein contains the Aβ sequence (Wasco et al.,
1992, 1993). In mouse models, mutants in which individual APP gene family members are

57

knocked out develop with mild phenotypes, but appear mostly wild type (Heber et al., 2000; von
Koch et al., 1997). By contrast, combinatorial knockouts of the APP gene family members
(APP-/-/APLP2-/-, APLP1-/-/APLP2-/-, or APP-/-/APLP1-/-/ APLP2-/-) result in in utero or early
postnatal lethality (Heber et al., 2000; Herms et al., 2004; von Koch et al., 1997); in addition, the
triple knockout also shows type II lissencephaly and disruptions in cortical migrations (Herms et
al., 2004). Interestingly, cleaved and secreted APP, sAPP, introduced in APP-/- or the APP-//APLP2-/- mutant mice rescues the APP knockout phenotypes (Ring et al., 2007) and the lethality
seen in APP-/-/APLP2-/- mutant mice (Ring et al., 2007), indicating that the secreted extracellular
domain of APP is necessary and sufficient for viability. These findings suggest that the APP
family is essential for viability and different members have overlapping functions, despite the
lack of the Aβ sequence in APLP1 and APLP2. However, the specific functions of APP have
been difficult to elucidate.
The nematode C. elegans has only one APP-related gene, apl-1 (Daigle and Li, 1993). Like
its mammalian counterparts, APL-1 is a single-pass transmembrane protein, with a relatively
large extracellular domain and a small cytosolic domain (Daigle and Li, 1993; Kang et al., 1987).
The extracellular domain contains the E1 and E2 domains characteristic of the mammalian APP
proteins and the cytoplasmic domain contains high sequence similarity to APP (Daigle and Li,
1993). Similar to APLP1 and APLP2, APL-1 does not contain the Aβ fragment (Daigle and Li,
1993; Wasco et al., 1992, 1993). Like the APP family, apl-1 has an essential function: knockout
of apl-1 results in larval lethality during the first to the second larval stage transition (Hornsten et
al., 2007; Wiese et al., 2010). The apl-1(yn10) knockout allele does not produce any detectable
levels of APL-1 protein (Hornsten et al., 2007). The lethality of apl-1 knockouts can be rescued
by re-introducing an apl-1 genomic fragment or by re-introducing a fragment encoding only the
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APL-1 extracellular domain (Hornsten et al., 2007). Hence, the cleaved APL-1 fragment, sAPL1, acts during early development and is sufficient for viability.
The only viable apl-1 mutant isolated thus far, apl-1(yn5), contains a deletion mutation that
removes the coding region for the transmembrane and cytoplasmic portions of the APL-1
protein; apl-1(yn5) mutants only produce the APL-1 extracellular fragment, again demonstrating
that the APL-1 extracellular domain is sufficient for viability (Hornsten et al., 2007).
Furthermore, pan-neuronal expression of APL-1 or APL-1(yn5) is sufficient to rescue the
lethality of apl-1 null mutants (Hornsten et al., 2007), suggesting that neuronal release of sAPL-1
is sufficient for viability. Hence, both the C. elegans and mouse rescues suggest an essential role
for sAPL-1/sAPP. However, the proteins with which sAPL-1/sAPP interact for these essential
functions are unknown. In this study, we are interested in using C. elegans as a model to provide
insights to the APP/APL-1 interactions that are essential for viability. We use both RNAi and
genetic screens to identify interacting proteins. We expect our screens to uncover loss of
function mutations in genes whose activity is downstream of apl-1 activity and gain of function
mutations in genes that become activated by apl-1 activity

II.4 MATERIALS AND METHODS
II.4.1 Strains
The N2 var Bristol strain was used as wild type; strains were grown and maintained on MYOB
plates (Church et al., 1995) containing OP50 Escherichia coli bacteria at 20oC using methods as
described (Brenner, 1974), unless noted. All mutations used are described in Wormbase
(www.wormbase.org) and include: LGI: bli-4(e937); LGII: rol-6(e187); LGIII: daf-2(e1368),
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vab-7(e1562); LGIV: unc-31(e928); LGV: dpy-11(e224); LGX: lon-2(e678), apl-1(yn5 and
yn10), dpy-8(e130).

II.4.2 Western blot analysis
Strains were fed either OP50 or apl-1 RNAi bacteria until the bacteria were depleted. Proteins
were extracted as described (Hornsten et al., 2007). Sample extracts (5 mg/ml) were used in
SDS-PAGE and Western blotting. Relative protein levels on Western blots were determined
using ImageJ and Image Studio Lite (LI-COR Biosciences).

II.4.3 Developmental timing and egg-laying rate assays
To synchronize worm populations ~15 gravid adult worms were placed into a bleach solution to
release the eggs. Hatched worms were raised at 20oC. Four days later, 10 synchronized adults
were placed onto a fresh plate and allowed to lay eggs for 1-1.5 hours at room temperature (2224oC). Eggs were counted to determine an egg-laying rate; F1 progeny were placed at 20oC to
allow development. After 70-72 hours, the developmental stages of the animals at 20oC were
scored according to their gonadal development and body size. For development at 25oC, animals
were scored after 48 hours. Each individual trial was performed with at least 3 plates of
synchronized eggs for each strain and always included wild-type animals as a control. For
statistical analysis for the egg-laying rate, one-way ANOVAs with Tukey post-test (95%
confidence intervals) were performed to assess similarity between groups and for developmental
timing, a chi-square test was performed using Prism 8.0 software (GraphPad).

II.4.4 Embryonic development at 270C
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Fourth larval stage (L4) animals were allowed to develop to day 1 adults at 270C overnight. Day
1 adults were allowed to lay eggs at 270C for ≥2 hours, after which the adults were killed and the
number of eggs was counted. After 24 hours, the number of unhatched eggs was counted. Each
trial was performed with at least 3 plates containing 4 to 5 synchronized adults; plates of wildtype animals and apl-1(yn5) were always run in parallel as controls. One-way ANOVAs with
Tukey post-test (95% confidence intervals) were performed (Prism 8) to evaluate the similarity
between different strains.

II.4.5 RNA interference assays
RNAi by feeding: day -1, a single RNAi clone (HT115 bacteria, which are maintained at -80oC
on Luria broth medium (LB) agar plates with 25 μg/ml carbenicillin and 12.5 μg/ml tetracycline)
was picked from the Ahringer library (Kamath et al., 2000) (Geneservice) and incubated in 1 ml
LB containing 100 μg/ml ampicillin (at 37°C, 280 rpm) overnight; day 0, the 1 ml bacterial
culture was transferred into 10 ml LB containing 100 μg/ml ampicillin and incubated for another
4-6 hours at 37°C at 280 rpm. 450 μl of the bacteria culture was spread onto MYOB plates
(Church et al., 1995) containing 400 mM of βD-isothiogalactopyranoside (IPTG) and 50 μg/ml
ampicillin and these RNAi plates were placed in 37°C overnight; day 1, eight L4 animals (Po)
were placed on bacteria lawn that express double-stranded RNA (dsRNA) of a target gene or
empty vector control (L4440) to knock down expression levels of the targeted gene; day 4, about
50 F1 L4 animals were transferred onto new plates containing the same dsRNA expressing
bacteria; day 5, about 10 F1 one day adults were transferred onto new plates containing the same
dsRNA expressing bacteria to lay eggs for 1-1.5 hours at 20oC; F2 eggs either placed at 20oC or
at 27oC; day 8, the F2 population was scored for developmental progression and survival. The
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Ahringer RNAi library was screened with the feeding method as described (Kamath et al., 2000);
Fig. 1). Heterozygous lon-2(e678) apl-1(yn10)/dpy-8(e130) animals were plated with bacteria
containing different RNAi clones, and F1 and F2 progeny were screened for the presence of Lon
animals. The isolated strains were further verified for the presence of the apl-1(yn10) allele by
PCR.

II.4.6 Mutagenesis screen and mapping
Heterozygous lon-2(e678) apl-1(yn10)/dpy-8(e130) or homozygous apl-1(yn5) animals were
mutagenized with 50 mM EMS as described (Brenner 1974). Mutagenized lon-2(e678) apl1(yn10)/dpy-8(e130) animals (Po) were singly plated and F1 or F2 adults were screened for the
presence of Lon animals (Fig. 2B). Mutagenized apl-1(yn5) mutants (Po) were singly plated and
F1 fourth larval stage progeny were grown on apl-1 RNAi plates (Fig. 3A). The F2 progeny
were screened for the presence of Lon animals, as well as on dpy-7 RNAi plates to ensure that
they did not inactivate the RNAi pathway. The suppressor mutations were determined to be
recessive or dominant and mapped by conventional methods (Brenner, 1974) and backcrossed 3
times.
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II.5 RESULTS
To identify genes that act in the same pathway as apl-1, we performed several RNAi and
mutagenesis screens. However, most of these screens were unsuccessful (Fig. 1). We were not
able to identify mutants unless we used the sensitized background of apl-1 knockdown in apl1(yn5) mutants (Fig. 2A). Through these screens we were able to isolate two mutants, yn41 and
yn42, which were able to bypass the need for apl-1 expression in an apl-1(yn5) apl-1 RNAi
background.

A

B
lon-2(e678) apl-1(yn10)/
dpy-8(e130)
RNAi
clones

Screened for Lon progeny
Outcome: No genes
identified

lon-2(e678) apl-1(yn10)/
dpy-8(e130)
Plate F1
progeny
Screened for F2 Lon progeny
Screened >150,000 haploid
genomes: No genes identified

Figure 1. Screening for suppressor mutations with an RNAi library or mutagenesis were
not successful. A. Heterozygous apl-1(yn10) mutants carrying flanking recessive marker
mutations, lon-2 in cis and dpy-8 in trans, were fed bacteria containing RNAi clones from the
Ahringer RNAi library. No suppressor mutations were identified. B. Heterozygous apl-1(yn10)
mutants carrying flanking recessive marker mutations, lon-2 in cis and dpy-8 in trans, were
mutagenized and F1 and F2 progeny were screened for Lon progeny. No suppressors were
identified. thunderbolt=EMS mutagenesis.
II.5.1 Genome-wide RNAi screens did not uncover any apl-1 suppressors
The Ahringer RNAi library contains E. coli carrying RNAi constructs targeting 16,000 C.
elegans genes, which accounts for approximately 80% of the C. elegans genome (Kamath et al.,
2000). apl-1 heterozygous null mutants with flanking cis and trans recessive markers lon-2 and
dpy-8 (genotype: lon-2 apl-1(yn10)/dpy-8) were fed bacteria containing the different clones (Fig.
2A). We anticipated identifying genes, which when knocked down, bypassed the need for apl-1,
therefore yielding viable Lon, apl-1(yn10) progeny. Knockdown of 15 to 20 genes per
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chromosome resulted in Lon progeny; however, each knockdown was determined to be a false
positive due to recombination because: 1) their progeny were not true breeding for the Lon
phenotype; and 2) PCR analysis of these Lon mutants revealed that they were not homozygous
for the apl-1(yn10) allele. Overall, we were unable to identify any genes, which when knocked
down, were able to bypass the need for APL-1 activity

II.5.2 Two suppressors were isolated in mutagenesis screens
To isolate suppressors by genetic screens, we mutagenized the apl-1(yn10) heterozygous mutants
carrying the flanking cis lon-2 and trans dpy-8 recessive markers (Fig. 2B). The F1 and F2
progeny were screened for the presence of dominant (F1 progeny) and recessive (F2 progeny)
suppressor mutations by identifying Lon animals, which presumably also carried the
homozygous apl-1(yn10) allele. We screened >150,000 haploid genomes and isolated 11 Lon
mutants. Amongst these 11 mutants, 2 were not true-breeding Lon animals (genotype: lon-2/lon2 dpy-8 heterozygotes), 8 were sterile, and 1 was uncoordinated and sterile. We were unable to
further characterize the sterile mutants due to their lack of progeny and because the heterozygous
F1 progeny could not be recovered.
We devised an alternate approach to isolate suppressors. Although our lab and others
found that apl-1 knockdown by RNAi did not lead to lethality (Hornsten et al., 2007; Wiese et al.,
2010), apl-1 knockdown by RNAi in apl-1(yn5) mutants leads to a completely penetrant lethality
(Ewald et al., 2012a). Hence, we re-designed our screen so that we mutagenized apl-1(yn5)
mutants whose F1 progeny were plated on apl-1 RNAi plates (Fig. 2A). We screened over
248,000 haploid genomes and identified 8 suppressors, which included 2 mutants with dominant
mutations and 6 mutants with recessive mutations. The two mutants with dominant mutations
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and 4 of the recessive mutants were unresponsive to dpy-7 RNAi; that is, on dpy-7 RNAi plates,
no Dpy animals were detected. Hence, these mutants were eliminated from further study
because they were likely to have mutations affecting RNAi responsiveness. The remaining two
recessive suppressors, yn41 and yn42 produced Dpy progeny when dpy-7 was knocked down by
RNAi feeding in an apl-1(yn5) background, suggesting that these mutants did not affect RNAi
pathways. Both suppressor mutations mapped to chromosome 4 (Table S1) and appear to belong
to the same complementation group (Table S2).
Although the apl-1(yn5) mutants are viable at 20oC, they show several phenotypes,
including a low rate of lethality, a smaller brood size, and locomotory defects (Hornsten et al.,
2007). In addition, when apl-1 expression is knocked down by RNAi, apl-1(yn5) mutants die
with 100% penetrance during the L1 to L2 transition (Ewald et al., 2012a). By contrast, 74.9% of
yn41; apl-1(yn5), and 88.4% of yn42; apl-1(yn5) mutants survived through to adulthood and
produced viable progeny when subjected to apl-1 RNAi (Fig. 2B; Table S3). These results
suggest that activity of yn41 and yn42 is epistatic to that of apl-1 and that their loss can bypass
the need for apl-1 activity.
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Figure 2. The yn41 and yn42 mutations suppress the apl-1(yn5) apl-1 RNAi lethality at
different rates. A. Schematic of screen used to isolate suppressor mutants. apl-1(yn5) mutants
were mutagenized (thunderbolt) and F2 progeny were grown on apl-1 RNAi plates. Two
suppressor mutants were isolated, yn41 and yn42. B. The viability of the suppressor mutants was
assessed. Each dot represents one apl-1 RNAi plate in which 5 day 1 adults were plated and
allowed to lay eggs for 2 hours. Eggs were allowed to hatch and develop for 72 hours, after
which surviving egg-laying adult progeny were quantified. apl-1(yn5) mutants showed a
completely penetrant lethality. yn41 single and yn41; apl-1(yn5) double mutants were
significantly different from wild type (****, p<0.0001, one-way ANOVA, Dunnett’s posthoc
test). yn41 and yn42 single and yn41; apl-1(yn5) and yn42; apl-1(yn5) double mutants were
significantly different from apl-1(yn5) (++++, p<0.0001, one-way ANOVA, Dunnett’s posthoc
test). Number of trials<9, number of progeny>412.
II.5.3 The yn41 mutation impacts viability at 200C
At 200C, approximately 86% of apl-1(yn5) mutants are viable and survive through adulthood,
when they are capable of producing offspring (Ewald et al., 2012a). Similarly, we found that
88.0% of apl-1(yn5) mutants were viable at 200C (Table S4). To determine the effect of yn41
and yn42 mutations on viability, we calculated viability in the presence or absence of an apl1(yn5) mutant background. In a wild-type or apl-1(yn5) background, the rate of lethality was
enhanced in yn41 mutants: yn41 and yn41; apl-1(yn5) mutants showed only 67.4% and 70.5%
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viability, respectively (Fig. 3; Table S4). These data suggest that independent of the yn5
mutation yn41 mutants show decreased viability.
By contrast, the yn42 mutation did not appear to affect viability. Wild type and yn42
mutants had similar levels of viability. Similarly, there was no significant difference in mean
viability between apl-1(yn5) and yn42; apl-1(yn5) mutants (Fig. 3; Table S4), suggesting that
yn5 alone is responsible for decreased viability in yn42; apl-1(yn5) double mutants.

Figure 3. A mutation in yn41 but not yn42 affects viability. A. Schematic of protocol. Day 1
adults of different strains were killed after laying eggs for at least 2 hours. Eggs were allowed to
develop at 200C for 48-72 hours. The number of larval or adult animals was counted. B. The
ratio of animals counted 48-72 hours to the total number of eggs was used to determine % viable.
Each dot indicates measurements for 1 or 5 animals. *p<0.05, ****p<0.0001, significantly
different than wild type, ++p<0.01, ++++p<0.0001, significantly different from apl-1(yn5), one-way
ANOVA, Tukey’s posthoc test. Number of trials=6.
II.5.4 Embryonic development is affected in yn41 mutants
Because apl-1(yn5) shows an embryonic lethality at 27oC (Ewald et al., 2012a), we were
interested in whether this elevated temperature also impacted embryonic development in yn41
and yn42 mutants. Adults were allowed to lay eggs at 27oC for 2 hours and 24 hours later, we
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counted the number of unhatched eggs. We found that yn41 single and yn41; apl-1(yn5) double
mutants laid significantly more eggs that did not hatch compared to other strains (Fig. 4; Table
S5), suggesting that independent of apl-1, yn41 activity impairs embryonic development. By
contrast, yn42 and yn42; apl-1(yn5) showed no significant difference in the number of unhatched
eggs compared to wild type and apl-1(yn5) mutants, suggesting that yn42 activity is not involved
in embryonic development.

Figure 4. yn41, but not yn42, is involved in embryonic development. yn41 and yn41;apl1(yn5) mutants showed significant differences in the number of unhatched eggs as compared to
wild type at 27oC (****p<0.0001 as compared to wild type, ++++p<0.0001 as compared to apl1(yn5), +++ p<0.001 as compared to apl-1(yn5); one way ANOVA, Tukey’s posthoc. Each dot
represents one trial, in which eggs from 5 Pos were scored.
II.5.5 yn41 enhances the egg-laying defect observed in apl-1(yn5) mutants
On average, wild type animals lay 7.3 ± 0.3 eggs per hour, while apl-1(yn5) mutants lay
significantly less (4.3 ± 0.2 eggs per hour) at 20oC (Ewald et al., 2012b). Similarly, we found
that wild type laid 6.23 ± 0.29 eggs per hour (n=75) and apl-1(yn5) mutants laid significantly
less (4.47 ± 0.24 eggs per hour; n=75) (Fig. 5; Table S6). yn41 mutants had a similar egg-laying
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rate as wild type (Fig. 5; Table S6). However, yn41; apl-1(yn5) laid an average of 3.34 ± 0.28
eggs per hour (n=75), which is significantly lower than wild type and apl-1(yn5) alone (Fig. 5;
Table S6). This result suggests that yn41 is working in parallel with apl-1 to influence egg-laying
rates. As with viability, the yn42 mutation did not affect egg-laying rates. yn42 mutants laid 5.91
± 0.29 eggs per hour (n=75), similar to wild type (Fig. 5; Table S6). Like apl-1(yn5) mutants,
yn42; apl-1(yn5) double mutants laid 4.12 ± 0.23 eggs per hour (n=75). Together, these data
suggest that yn42 does not impact C. elegans egg-laying rate.

Figure 5. yn41 enhances the egg-laying defect observed in apl-1(yn5) mutants. Fourth larval
stage animals were grown overnight to become day 1 adults at 20oC (A) or 27oC (B). One to five
day-one adults were allowed to lay eggs for >2 hours, after which the parents were killed and the
number of eggs counted. Each dot represents eggs laid from either 1 or 5 animals. **p<0.01, ***,
p<0.001, ****p<0.0001 significantly different than wild type, +p<0.05, ++p<0.01, ++++p<0.0001
significantly different from apl-1(yn5), one-way ANOVA, Tukey’s (20oC) or Dunnett’s (27oC)
posthoc test. Number of trials=6.
II.5.6 yn41 and yn42 mutations cause an egg-laying defect at elevated temperatures
apl-1(yn5) mutants show decreased viability when exposed to elevated temperatures (270C)
(Ewald et al., 2012a). However, the egg-laying rates of apl-1(yn5) mutants did not change with
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the elevated temperature (Fig. 5, Table S6). Like apl-1(yn5) mutants, yn41 and yn42 mutants
showed decreased egg laying rates that were significantly different from wild type at 27oC; the
yn41 and yn42 mutations also enhanced the apl-1(yn5) egg laying defects (Fig. 5, Table S6).
These data suggest that apl-1 and yn41/yn42 work in different pathways to regulate egg laying at
270C.

II.5.7 yn41 and yn42 activity affect C. elegans lifespan
Wild-type animals have a mean lifespan of 14-18 days (Johnson and Wood, 1982; Klass and
Hirsh, 1976). Under our laboratory conditions, we found that wild type have a mean lifespan of
14.2±0.1 days; apl-1(yn5) mutants have a shortened lifespan (12.5±0.1 days) compared to wild
type (Ewald et al., 2012a). In our current experiments, we found that wild type and apl-1(yn5)
had a mean lifespan of 15.7±0.3 days (n=247) and 11.5±0.3 days (n=223), respectively (Table
S7). yn41 single mutants had a similar, shortened lifespan [12±0.4 days (n=103)] as apl-1(yn5)
mutants (Fig. 6; Table S7); the decreased lifespan of yn41 mutants was not enhanced in an apl1(yn5) background [12.3±0.4 days (n=114)], suggesting that yn41 and apl-1 act in the same
pathway to affect lifespan. The lifespan defect in yn42 mutants were not as severe; the mutants
had an intermediate lifespan [14.5±0.4 days (n=118)] compared to wild type and apl-1(yn5)
mutants (Fig. 6; Table S7). The yn42; apl-1(yn5) double mutants showed a similar, shortened
lifespan [11.3±0.3 days (n=195)] as apl-1(yn5) mutants. Together, these data suggest that yn41,
yn42, and apl-1 function in the same pathway to influence C. elegans lifespan.
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Figure 6. yn41 and yn42 activity affect lifespan. apl-1(yn5) and yn41 mutants have a shortened
lifespan. This shortened lifespan was not further increased in the double mutant yn41; apl-1(yn5).
By contrast, yn42 mutants had a lifespan that was intermediate to apl-1(yn5) and wild type. The
yn42; apl-1(yn5) mutants showed a lifespan that was similar to apl-1(yn5) mutants. For each
strain, 6 trials containing over 100 animals total were performed. All strains were significantly
different from wild type. Log-rank and Gehan-Breslow-Wilcoxon tests.
II.5.8 Effect of apl-1 knockdown on APL-1 protein levels in yn41 and yn42 mutants
To gain insights into protein expression levels and protein modification in yn41 and yn42
mutants, we analyzed western blots. apl-1(yn5) mutants contain higher levels of sAPL-1 than the
total levels of full-length APL-1 and sAPL-1 combined in wild-type animals, presumably
because the extracellular domain is constitutively released in apl-1(yn5) mutants (Hornsten et al.,
2007). Western blot analysis showed that there are differences in APL-1 levels in extracts from
yn41 and yn42 mutants (Fig. 8). Extracts from yn42 mutants had lower levels of APL-1 than wild
type and apl-1(yn5); however, in an apl-1(yn5) background, APL-1 levels were comparable to
those from apl-1(yn5) mutants. By contrast, extracts from yn41 and yn41; apl-1(yn5) mutants
showed comparable levels of APL-1. In addition, in yn41; apl-1(yn5) and yn42; apl-1(yn5)
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mutants, we observed an additional protein that is slightly larger and not present in apl-1(yn5)
extracts. We confirmed that yn41; apl-1(yn5) and yn42; apl-1(yn5) are indeed homozygous for
the yn5 deletion by PCR (Fig. 7B), and suggest that this protein represents a modified
(glycosylated and/or phosphorylated) sAPL-1 that is normally not detectable in wild-type of apl1(yn5) extracts.
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Figure 7. The yn41 and yn42 mutations affect APL-1 protein levels inversely. Extracts from
apl-1(yn5) mutants showed higher levels of sAPL-1 equivalents than wild-type total APL-1
protein. A. yn42 and yn42; apl-1(yn5) extracts contained lower levels of APL-1 protein than
wild type and apl-1(yn5). yn41 extracts showed higher levels of APL-1 than wild type; however,
yn41; apl-1(yn5) extracts had lower levels of APL-1 compared to apl-1(yn5) alone. Upper panel,
probed with an antiserum against the extracellular domain of APL-1; lower panel probed with an
α-tubulin monoclonal antibody, which was used as a loading control. Asterisk indicates fulllength APL-1, double asterisks indicate the cleaved APL-1 fragment, sAPL-1 of APL-1(yn5), +
likely indicates glycosylated and/or phosphorylated sAPL-1. The white bar indicates where the
image of the gel was spliced to remove the molecular weight markers. Number of trials=3, 20µl
at 5 mg/ml was loaded for each sample. B. Levels of APL-1 in wild type grown OP50 were
higher than APL-1 levels in wild type and yn42 when apl-1 was knocked down by RNAi feeding,
but lower than APL-1 levels in yn41 were treated with apl-1 RNAi. APL-1 levels in apl-1(yn5)
mutants grown on OP50 were higher than APL-1 levels in both yn41 and yn42. Number of
trials=3. C. Upper panel shows PCR products derived from using primers within the yn5
deletion. PCR products were generated in wild type, yn41 and yn42, all of which contained fulllength apl-1; no PCR product was detectable in apl-1(yn5), yn41; apl-1(yn5), and yn42; apl1(yn5), all of which had the yn5 deletion in apl-1. Lower panel shows PCR products using
primers flanking the apl-1 coding region. Amplification of genomic DNA from wild type, yn41
and yn42, all of which contained full-length apl-1, yielded larger products than apl-1(yn5), yn41;
apl-1(yn5), and yn42, which contained the apl-1(yn5) deletion.
II.5.9 Deep sequencing of yn41 and yn42 reveals possible gene candidates
Although our complementation test (Table S2) suggested that yn41 and yn42 are alleles of the
same gene, deep sequencing of the DNA from both mutants revealed different possible gene
candidates. The yn41 sequencing showed three possible candidates, while the yn42 sequencing
highlighted 11 possible candidates (Table S8). To narrow down the field of candidates, we used
RNAi to knockdown activity of candidate genes in lon-2(e678) apl-1(yn10)/dpy-8(e130)
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heterozygous mutants and screened for the presence of surviving Lon animals. Lon animals
were verified for homozygosity of apl-1(yn10) by PCR to rule out possible recombinant animals.
Of the three possible yn41 candidates, RNAi clones were available for only two candidates;
knockdown of these two candidates did not reveal any Lon animals. By contrast, knockdown of
candidates for yn42 were more fruitful. Knockdown of cdh-5/PCDH15 and tgt-1/QTRT1
resulted in the presence of Lon animals, and these animals were confirmed to be homozygous for
apl-1(yn10). We suggest that yn42 corresponds to either cdh-5/PCDH15 or tgt-1/QTRT1; no
molecular lesions were present in yn41 in the cdh-5/PCDH15 or tgt-1/QTRT1 coding and
intronic sequences. The closest polymorphisms in yn41 were 84 kbp upstream of the cdh5/PCDH15 coding region and 18 kbp downstream of the tgt-1/QTRT1 coding region. We were
unable to test Y43D4A.6/CHEK1, glct-6/B3GAT1, and R102.11 because clones were not present
in the Ahringer RNAi library (Table S8). The sequencing data suggest that yn41 and yn42
correspond to alleles of different genes; we are naming them moa-3(yn41) and moa-4(yn42).
Their complementation suggests that there is non-allelic non-complementation.

II.6 DISCUSSION
Like the APP gene family, loss of apl-1 leads to lethality. We have previously
determined that only the extracellular fragment of APL-1 is necessary for viability. To identify
genes that act in concert with apl-1 to confer viability, we performed several RNAi and
mutagenesis screens. Our genome-wide RNAi screen did not reveal any possible candidates.
There were several limitations in our genome-wide RNAi screen. For instance, the Ahringer
library only covers 80% of the genes in the C. elegans genome (Boutros and Ahringer, 2008;
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Kamath et al., 2000); thus, it is plausible that a bypass suppressor is within the 20% of the
genome that was not covered by the library. Another limitation was the variability of
knockdown levels amongst genes when performing RNAi: different genes are knocked down to
different levels and genes expressed in neurons are relatively refractory to RNAi (Asikainen et
al., 2005; Kamath et al., 2000; Timmons et al., 2001). Furthermore, the degree of knockdown
may not be as powerful as a complete gene knockout; therefore, we may have encountered a
gene of interest, but the degree to which its transcript levels were decreased was not sufficient to
elicit a survival response in the absence of apl-1. Lastly, apl-1 may be interacting with multiple
genes simultaneously in order to enable viability. Hence, rather than knocking down the
expression of one gene, we would need to knockdown multiple genes to see an effect. A
multitude of small interactions between apl-1 and other genes may be necessary for survival, but
the RNAi screen would not pick up such genes.
By contrast, our mutagenesis screen to recover homozygous apl-1(yn10) mutants from
heterozygous parents yielded 9 sterile mutants whose progeny could not be further characterized.
These results indicate that we need to follow the heterozygous mutant parents more quickly in
future iterations of this screen. Additionally, our screen may have uncovered recessive maternal
effect genes, whose products are necessary for embryonic development. While the heterozygous
hermaphrodites are able to produce viable homozygous progeny, the homozygous mutants will
be unable to produce wild type protein to allow for the development of viable offspring. Overall,
this screen emphasizes the complexity of the multiple roles in which apl-1 and its interacting
partners are involved
In the sensitized apl-1(yn5) RNAi mutagenesis screen, we isolated 6 recessive and 2
dominant mutants. Of these, six mutants were not further characterized because they were likely
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inactivating the RNAi pathway, thereby showing that our screen was effective. This low rate of
mutant yield of two mutants suggests that we should continue mutagenesis screens until we
achieve saturation. Our low mutant yield also informs us that apl-1 has an early involvement in
multiple critical and divergent pathways. Consequently, mutations in a suite of downstream
genes, in concert, may be required to bypass the need for apl-1 activity.
We identified two mutants, yn41 and yn42, that modify the activity of apl-1 to achieve
viability in an apl-1(yn5), apl-1 RNAi context and did not complement. We characterized these
mutants and found that yn41 presented more severe phenotypes than yn42, with respect to egglaying rates, embryonic development, and overall viability. For example, we showed that yn41
enhanced the apl-1(yn5) egg-laying and embryonic development defects whereas yn42 did not.
Additionally, yn41 showed a decrease in lifespan, comparable to apl-1(yn5) while yn42 showed
significantly increased lifespan, as compared to apl-1(yn5). Overall, both mutants were able
suppress the apl-1(yn5) lethality when apl-1 was knocked down by RNAi feeding; however,
neither was able to suppress the other apl-1(yn5) defects. These data suggest that the pathways
in which apl-1, yn41, and yn42 function to confer viability are separate and independent from the
other pathways involving apl-1.
We narrowed down yn42 to mutations in two possible genes: cdh-5/PCDH15 and/or tgt1/QTRT1. cdh-5 is the PCDH15 (protocadherin-related 15) ortholog. The role of cdh-5 in C.
elegans is not understood; however, it is predicted to bind calcium ions (Wormbase.org).
Mammalian PCDH15 is a single-pass transmembrane protein that forms a calcium-dependent
heterodimer with CDH23 (cadherin 23) to maintain cell-cell adhesion and facilitate
mechanotransduction (Richardson and Petit, 2019). In C. elegans, cdh-5 signal transduction may
be responsible for modulating apl-1 expression levels. The yn42 mutation corresponds to a
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D376N, which changes an acidic residue to a neutral residue. This residue change in CDH-5
may disrupt its signaling capabilities and/or its binding to sAPL-1, thereby allowing sufficient
levels of sAPL-1 in an apl-1(yn5), apl-1 RNAi context for viability.
tgt-1, the QTRT1 (queuine tRNA-ribosyltransferase catalytic subunit 1) ortholog, is also
poorly understood in C. elegans. QTRT1 in mammals catalyzes the exchange of guanine for
queuine in the wobble position of tRNAs, and is reported to physically interact with the APP
cytosolic cleavage product resulting from γ-secretase activity and with the adaptor protein Fe65
(Huttlin et al., 2017). The APP cytosolic fragment complexes with Fe65, and the complex is
translocated to the nucleus where it initiates transcription of unknown genes (Cao and Südhof,
2001), which are presumably necessary for viability (Hornsten et al., 2007). The functional
involvement of QTRT1 with the complex or with the complex’s individual components is
unknown. We speculate that tgt-1/QTRT1 is responsible for maintaining optimal APL-1
signaling levels. The corresponding yn42 mutation causes a P234L replacement; prolines
provide conformational rigidity and facilitate beta turns. The leucine substitution may disrupt
TGT-1 interactions with APL-1, thereby allowing the minimal apl-1 signaling necessary for
viability, in the presence of apl-1 knockdown.
Further analysis must be conducted to confirm to the genetic interaction between apl-1
and cdh-5/PCDH15, tgt-1/QTRT1, and the other candidate genes. This can be achieved by
generating double mutants using mutant alleles of the candidate genes in an apl-1(yn5) mutant
background, and assessing their survivability in apl-1 RNAi. We can also determine whether
there is a physical interaction between APL-1 and the candidate genes by coimmunoprecipitation experiments, and investigating whether or not there is in vivo colocalization.
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In yn41 mutants, we did not find polymorphisms within either coding regions for cdh5/PCDH15 or tgt-1/QTRT1. Instead, yn41 showed polymorphisms 84 kbp upstream of the cdh5/PCDH15 coding region and 18 kbp downstream of the tgt-1/QTRT1 coding region. Either
these polymorphisms are in key regulatory regions, or alternatively, yn41 and yn42 have
mutations in different genes but show non-allelic, non-complementation. We, therefore,
searched chromosome V of yn41 for additional molecular lesions because our mapping data
showed similar values for both chromosome IV and V (Table S1). Chromosome V contains
lesions in 24 different candidate genes (Table S9), which should be studied to determine whether
any of these candidates correspond to yn41.
Lastly, the presence of the flanking markers lon-2(e678) and dpy-8(e130) in our screens
may have affected our ability to identify interacting genes. For instance, based on its crystal
structure, and like the E1 and E2 domains of APP (Mok et al., 1997), the E1 and E2 domains of
APL-1 are predicted to bind heparin sulfate proteoglycans (HSPGs) (Hoopes et al., 2010), a
family of proteins that regulate growth factor signaling. Interestingly, lon-2 encodes an HSPG
that negatively regulates dbl-1, the C. elegans ortholog of the bone morphogenetic protein
(BMP) (Gumienny et al., 2007). The interaction between APL-1/APP family and HSPGs have
not fully been investigated; however, the presence of the lon-2(e678) mutation may have
introduced a confounding variable that decreased the possibility of identifying interacting genes.
In summary, we have identified mutants and their corresponding gene products that are
critical for the normal function of apl-1. Although much more work is required to definitively
outline the pathways involving apl-1 and these interacting genes, our findings in C. elegans will
continue to give clues to the role of the APP gene family in mammals.
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II.8 SUPPLEMENT

Strain

II

I

Chromosome

238

209

166

Total assayed

38

29

31

Total dead

15.97

13.88

18.67

Percentage dead

Table S1. The yn41 and yn42 mutations map to chromosome 4.

yn41; apl-1(yn5)

III

29.48

5.33

51

13

10.70

173

244

26

24.48

IV

I
243

59

36.29

22.40

II

241

90

17.53

56

III

248

44

250

IV

251

V
yn42; apl-1(yn5)

V

80

apl-(yn5)

Strain

15/15

2/12

Number of apl-1 RNAi plates with viable F1s

Table S2. yn41 and yn42 do not complement.

yn41/yn42; apl-1(yn5)

Matings were established on apl-1 RNAi plates using 1 yn41 or yn42 hermaphrodite with 8 to 10 yn41 or yn42 males, respectively.

Successful matings were determined by the presence of males amongst the resulting F1 progeny. 4 days after matings, F1s were
scored. Number of trials=3.

81

13
70

65

569

782

741

Total no. of
eggs

324

348

3

711

Total no. of
adults

0.749 ± 0.061****,++++

0.613 ± 0.035****

0.003 ± 0.002****

Fraction of
surviving adults ±
SEM1
0.975 ± 0.053++++

Table S3. The yn41 and yn42 mutations suppress the apl-1(yn5) apl-1 RNAi lethality

Wild-type
14
50
412

No. of P0
assayed

apl-1(yn5)
10
55

No. of
trials

yn41
11

0.976 ± 0.016++++

Strain (genotype)

yn41; apl-1(yn5)

623

0.884 ± 0.020++++

635

582

45

658

9
55

yn42
11

p<0.0001 significantly different from apl-1(yn5).

One-way ANOVA, Dunnett’s or Tukey’s posthoc test, *p<0.05, ****p<0.0001 significantly different than wild type, ++p<0.01,

yn42; apl-1(yn5)
1
++++

82

yn41

apl-1(yn5)

wild type

6

6

6

No. of
trials
6

75

72

75

75

No. of P0
assayed
75

940

1363

774

1327

1041

Total no. of
eggs
1483

907

1342

559

926

956

No. of
adults
1470

0.923 ± 0.030

0.993± 0.011++

0.705 ± 0.033****,++++

0.674 ± 0.024****,++++

0.880 ± 0.021*

Fraction of eggs to
adulthood ± SEM1
0.990 ± 0.010

Table S4. The yn41 mutation enhances the lethality of apl-1(yn5) mutants

yn41; apl-1(yn5)
6
75

Genotype

yn42
6

One-way ANOVA, Tukey’s posthoc test, *p<0.05, ****p<0.0001 significantly different than wild type, ++p<0.01, ++++p<0.0001

yn42; apl-1(yn5)
1

significantly different from apl-1(yn5). Experiments were performed at 20oC.
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apl-1(yn5)

wild type

3

3

3

No. of
trials
27oC

9

9

9

9

No. of
P0
assayed
27oC

195

245

314

439

Total no.
of eggs
27oC

90

107

11

6

Total no. of
unhatched eggs
27oC

0.461

0.436

0.035

0.01

Mean fraction
of unhatched
eggs ± SEM1

Table S5. The yn41 mutation affects viability

yn41
3

Genotype)

yn41; apl-1(yn5)

0.014
0.097

4
26

268
268

9
9

3
3

yn42
yn42; apl-1(yn5)

One-way ANOVA, Tukey’s (20oC) or Dunnett’s (27oC) posthoc test, **p<0.01, ***, p<0.001, ****p<0.0001 significantly different

than wild type, +p<0.05, ++p<0.01, ++++p<0.0001 significantly different from apl-1(yn5).

1

84

apl-1(yn5)

wild type

6

6

6

75

75

75

75

809

1327

1041

1483

3.33 ± 0.28****,+

5.91 ± 0.26++

4.47 ± 0.24****

3

3

3

36

36

36

No. of
P0
assayed
27oC
36

97.5

122.5

157

219.5

2.71 ± 0.37***

3.40 ± 0.71**

4.36 ±0.46

No. of
eggs/hr/adult ±
SEM1
27oC
6.10 ± 0.29

Total no.
of eggs
27oC

yn41
6

Table S6. The yn41 and yn42 mutations enhance the apl-1(yn5) egg-laying defect
Genotype)
No. of
No. of P0 Total no. No. of
No. of
trials
assayed
of eggs eggs/hr/adult ±
trials
20oC
20oC
20oC
SEM1
27oC
20oC
6.23 ± 0.29
3

yn41; apl-1(yn5)

3.74 ±0.75**

3.72 ± 0.27**

134.5
134

36
36

3
3

5.91 ± 0.29++
4.12 ± 0.23****

1334
976

75
75

6
6

yn42
yn42; apl-1(yn5)

One-way ANOVA, Tukey’s (20oC) or Dunnett’s (27oC) posthoc test, **p<0.01, ***, p<0.001, ****p<0.0001 significantly different

than wild type, +p<0.05, ++p<0.01, ++++p<0.0001 significantly different from apl-1(yn5).

1

85

of trials

number

Total

247

animals

number of

Total

11.51 ±0.26****

15.70 ±0.31

10

12

17

Table S7. The yn41 and yn42 mutations do not enhance the apl-1(yn5) lifespan defect at 200C

6
223

11.09 ±0.40****

13

(days)

Median

Wild-type
6
103

12.29 ±0.37****

Mean survival ±

apl-1(yn5)
6
114

14.50 ±0.40**, ++++ 15

Strain (genotype)

yn41
6
118

11.31 ±0.30****

survival

yn41; apl-1(yn5)
6

195

SEM (days)

yn42
6

12

yn42; apl-1(yn5)

****p<0.0001, significantly different from wild type, ++++p<0.0001, significantly different from apl-1(yn5), log-rank and GehanBreslow-Wilcoxon tests.
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Total number of P0
used
30
0/30

Number of plates
with LON animals
0/30

No

Homozygous for
yn10 by PCR
No

Table S8. Candidates from genomic sequencing
Total number of
trials
3
30

RNAi
cla-1
3

ND*

sas-6
Y43D4A.6

No

Yes

3/30

No

6/30

30

7/30

No

30

3
30

3/30

No

3

F56D5.9
3

30

1/30

No

cdh-5

magi-1
3

30

6/30

No

Yes

F38H4.4
3

30

4/30

No

5/30

wdfy-3
3

30

0/30

30

ZK896.5
3

30

3

F49E8.7

3

tgt-1

F35H10.10

87

R102.11

glct-6

ND*

ND*

*ND= not determined, RNAi clone not in library
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daam-1

Gene Description

3629C>T

398C>T

Coding region change in longest transcript

Ala1210Val

Ser133Phe

Amino acid change in longest transcript

Table S9. yn41 gene candidates on LG V with non-synonymous changes

abt-4

Pro221Ser

Ser2Phe

661C>T

5C>T

Met498Ile

C14C6.8

srx-122
1494G>T

Pro700Gln

Gly15Glu

C07G3.8
2099C>A

Arg3Gln

44G>A

catp-2
8G>A

Pro193Ser

F41B5.1

Y49G5B.1

577C>T

Trp494*

Gln274*

F08F3.6

1481G>A

Pro279Ser

820C>T

sago-1

835C>T

cyp-33C9

ZK1055.7

89

scyl-1

R31.2

K07C5.2

unc-41

dop-2

K07C11.10

F58G4.2

ets-7

fxba-105

C13A2.5

str-204

ugt-38

1265C>T

1204C>T

862G>A

1805C>T

1831G>A

286C>T

187-155G>A

F19F10.5:c.520C>T

C02H6.2:c.784C>T

1373G>A

F10D2.1:c.839G>A

F10D2.7:c.1154C>T

Ala422Val

Gln402*

Gly288*

Ala602Val

Asp611Asn

Pro96Ser

Val233Ile

Pro174Ser

Gln262*

Ser458Asn

Cys280Tyr

Pro385Leu
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III.1 ABSTRACT
Mutations in the amyloid precursor protein (APP) gene or in the presenilin genes
that encode enzymes that cleave APP are correlated with familial Alzheimer’s disease.
APP is a transmembrane domain protein that can be cleaved to release an extracellular
fragment and further cleaved to release a cytoplasmic fragment and Aβ , which is deposited
in plaques characteristic of AD. The biological functions of full-length and cleaved
fragments of APP remain unclear. We are using Caenorhabditis elegans to examine the
fate of the cleaved fragments. Like the APP family, apl-1 has an essential function. Here,
we show that the extracellular fragment of APL-1 (sAPL-1) binds a heparan sulfate
proteoglycan, presumably to limit the diffusion of sAPL-1 so that it can bind its receptor to
initiate a signaling pathway.
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III.2 Article Summary
The etiology of Alzheimer’s disease (AD) remains unknown. Mutations in several genes,
including the amyloid precursor protein (APP), are correlated with inherited forms of AD as well
as protection against AD. Cleavage of APP releases an extracellular fragment, which is essential
for viability. Here, we report that the extracellular fragment of a C. elegans APP-related protein
APL-1 interacts with several heparan sulfate proteoglycans. We propose that these interactions
are to limit the diffusion of the extracellular fragment so that it can interact with proteins or
receptors in neighboring cells. These results suggest that human APP may similarly interact with
neighboring cells in its functions.
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III.3 INTRODUCTION
Alzheimer’s disease (AD) is an irreversible brain disorder that affects approximately 5.8
million Americans (Gaugler et al., 2019). The disease is characterized by progressive cognitive
decline, generally starting while patients are in their sixties. At the cellular level, the disease is
diagnosed by the presence of intracellular neurofibrillary tangles and extracellular senile plaques
(DeTure and Dickson, 2019). The major component of the tangles is a hyper-phosphorylated
form of the microtubule-associated protein tau; the major component of the plaques is the betaamyloid peptide (Aβ), which is a cleavage product of the amyloid precursor protein (APP)
(DeTure and Dickson, 2019). Mutations in APP have been found in a small number of earlyonset familial AD (FAD) cases; the majority of FAD mutations, however, are in the presenilin
genes, which encode enzymes within the gamma-secretase complex that cleaves APP. A
mutation in APP that interferes with Aβ production has been found to be neuroprotective,
suggesting that modifying APP processing can be beneficial (Jonsson et al., 2012). The effects
of a mutation in presenilin can be partially suppressed by homozygosity in APOE3 (ArboledaVelasquez et al., 2019); APOE, particularly APOE4 alleles, is the major susceptibility gene for
late-onset AD (Saunders et al., 1993).
APP is the founding member of the APP family of proteins, which includes APLP1 and
APLP2, and is the only member to contain the Aβ sequence (Müller et al., 2017). All APP
family members are type I transmembrane proteins that share conserved domains within their
extracellular (E1 and E2) and small cytoplasmic domains (Sandbrink et al., 1994; Slunt et al.,
1994; Sprecher et al., 1993; Wasco et al., 1992, 1993). The proteins are cleaved through two
pathways: the α/ γ-secretase and β/ γ-secretase pathways (Müller et al., 2017). In both pathways,
there is an initial extracellular cleavage by α-secretase or β-secretase to release a sAPPα or
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sAPPβ fragment, respectively, followed by a subsequent cleavage by the γ-secretase complex to
release an intracellular domain (AICD) and, in the case of the β/ γ-secretase pathway, also Aβ
(Haass et al., 1992, 1994; Müller et al., 2017). Extracellular release of Aβ presumably allows its
deposition into senile plaques. Over 200 binding partners to sAPP and AICD have been
identified (Deyts et al., 2016; Müller et al., 2017) and collated into an interactome (Perreau et al.,
2010), but the biological relevance of these interactions remain unclear.
The functions of APP and its cleavage products are also elusive. Single knockouts of
APP or APLP1 cause minor cognitive deficits (Heber et al., 2000; Ring et al., 2007). By
contrast, double knockouts of APP and APLP2 or APLP1 and APLP2 results in postnatal
lethality (Heber et al., 2000; von Koch et al., 1997). Knockout of the entire family results not
only in postnatal lethality, but also type II lissencephaly and cortical dysplasia (Herms et al.,
2004). Hence, the APP gene family has an essential function and family members have
overlapping functions. Surprisingly, phenotypes in APP single and the lethality of APP-APLP2
double knockouts can be rescued by just sAPPα (Weyer et al., 2011), suggesting that sAPPα
activates a signaling pathway that is essential for viability.
Activity by the extracellular domain of APP (sAPP) is implicated in several processes,
including neurite outgrowth, synapse formation, and neurogenesis (Müller et al., 2017; Turner et
al., 2003); whether any of these roles is essential for viability is unclear. The sAPP receptor
remains elusive, but sAPP does bind to many extracellular matrix components, such as laminin,
collagen, and heparan sulfate proteoglycans (HSPGs) (Small et al., 1992). In vitro binding
assays showed that the conserved E2 domain of APP family members binds heparin sulfate (HS),
which in turn mediates antiparallel dimerization of APP and APLP1 molecules (Dahms et al.,
2015; Lee et al., 2011; Wang and Ha, 2004; Xue et al., 2011). In addition to binding HS, APP
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was also able to bind the core protein component, proteoglycans (PGs), of HSPGs
(Narindrasorasak et al., 1991; Reinhard et al., 2013). APP contains at least four domains that
bind to HSPGs, including glypican and syndecan (Clarris et al., 1997; Reinhard et al., 2013;
Small et al., 1992, 1996; Williamson et al., 1996). Binding to these HSPGs is mediated via high
and low-affinity sites within the E2 and E1 domains of sAPP, respectively (Reinhard et al.,
2013). How sAPP binding to ECM molecules facilitates its functions remains unknown.
We are interested in identifying the sAPP pathway that is essential for viability and are
using the nematode Caenorhabditis elegans as our model. C. elegans contains only one APP
orthologue, apl-1; APL-1 is only processed by the α/ γ-secretase pathway and does not contain
the Aβ sequence (Daigle and Li, 1993; Hornsten et al., 2007; Link, 2006). Like the APP gene
family, loss of apl-1 results in lethality, which can be rescued by transgenes that encode APL-1
or sAPL-1, the equivalent of sAPPα (Hornsten et al., 2007). Furthermore, the apl-1 null lethality
can be rescued by pan-neuronal expression of apl-1 (Hornsten et al., 2007). Because C. elegans
is a self-fertilizing hermaphrodite, we are able to maintain lines of apl-1 knockouts if they carry
a rescuing transgene. APL-1 binds heparan sulfate through its E2 domain in vitro (Hoopes et al.,
2010), and has putative HSPG binding sites in its E1 domain as well (Hornsten et al., 2007). In
this study, we investigate the binding partners of sAPL-1 through an unbiased approach and
identify the receiving cells of the sAPL-1 signal. We have found that not only do multiple
components of the extracellular matrix (ECM) bind APL-1, but this binding is essential to enable
APL-1 function. We propose that the ECM functions to localize the sAPL-1 signal to nearby
neurons. These data may provide insights into how sAPPα functions.
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III.4 MATERIALS AND METHODS
III.4.1 Strains and Maintenance
C. elegans strains were grown and maintained on MYOB plates (Church et al., 1995) spread with
OP50/1 Escherichia coli as described (Brenner, 1974), unless noted. All mutations used are
described in (Wormbase.org) and include: LGII: unc-52(e998) (Rogalski et al., 1993); LGX:
lon-2(e678) (Gumienny et al., 2007), apl-1(yn5 and yn10) (Hornsten et al., 2007). Integrated
transgenic lines used were (transgenes are indicated in brackets: LGV: ynIs79 [APL-1::GFP]
(Hornsten et al., 2007); otIs670 [NeuroPal] (Yemini et al., 2019). The otIs696 [NeuroPal] line
was also used, but its genetic location is unknown (Yemini et al., 2019). For simplicity in the
text, we will only indicate the protein expressed by the transgenes, including GFP-tagged
proteins, in brackets.
20 to 30 L4 animals were placed on bacteria expressing empty vector (L4440) or bacteria
expressing double-stranded RNA of apl-1, dpy-7, unc-52, eat-6, and other genes of interest
(adapted from Yemini et al., 2019 (BioSourceScience)). Animals were allowed to develop to
day 1 adults overnight.

III.4.2 Immunoprecipitations and mass spectrometry
Different strains were grown, collected, and stored at -800C before use. Equal volumes of
0.5 mm zirconium oxide beads (Scientific Instrument Services) and 2X extraction buffer [(40
mM HEPES pH 7.5, 10% glycerol, 150 mM NaCl, 0.5% NP40, Halt Protease Inhibitor EDTAfree (Thermo Fisher Scientific)] were added to frozen worms and processed using a Bullet
Blender to obtain protein extracts. Protein concentrations were determined with a Bradford
assay kit according to the manufacturer’s protocol (Thermo Fisher Scientific).
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Lysates were incubated with either a polyclonal goat anti-GFP antiserum (Abcam) at
1:750-1,500, or monoclonal MH2 anti-perlecan/UNC-52 (Developmental Studies Hybridoma
Bank) at 1:60, in immunoprecipitation buffer (IP) [(50 mM HEPES pH 7.5, 150 mM NaCl, Halt
Protease Inhibitor EDTA-free (Thermo Fisher Scientific)]. Extracts were incubated with agarose
beads (Santa Cruz Biotechnology) on a rotator for two hours to overnight at 4oC. The beads and
extracts were centrifuged and washed with IP buffer three times. The immunoprecipitated
proteins were resuspended in IP buffer and 10X electrophoresis sample buffer (6x: 1.2g SDS,
0.01% bromophenol blue, 4.7 ml glycerol, 1.2 ml 0.5 M Tris, pH 6.8, 2.1 ml dH2O) and boiled
for 5 minutes before electrophoresis.
Samples were loaded into an 8% SDS polyacrylamide gel, and proteins excised from the
gel. The gel was digested by trypsin according to manufacturer’s protocols (Thermo Fisher
Scientific). Samples were further processed by the ASRC CUNY Mass Spectrometry Core
Facility in preparation for HPLC-ESI and peptide sequencing. Peptides were identified using
Mascot software. Using lysates from freshly harvested animals each time, this entire procedure,
from harvest to peptide analysis, was repeated 3 times.

III.4.3 Western blot analysis
Animals were collected and lysed as described above with the Bullet Blender; Western
blots were performed as described (Hornsten et al., 2007) with some modifications. Protein
levels were normalized as measured by Bradford assays. Roughly the same extract amount for
each strain was electrophoresed and transferred. After transferring to nitrocellulose (BioRad),
the blot was probed with an antiserum against the extracellular domain of APL-1 (1:5,000)
(Hornsten et al., 2007), a monoclonal anti-UNC-52/perlecan antibody (MH2 or MH3)
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(Developmental Studies Hybridoma Bank) at 1:100 (Rogalski et al., 1993), an anti-actin
monoclonal antibody (JLA20 or 8-7A5; Developmental Studies Hybridoma Bank (DSHB)) at
1:100-1:500, or an anti-alpha tubulin antibody (4A1 or AA4.3, DSHB) at 1:500; secondary
antibodies [(donkey anti-rabbit or donkey anti-mouse (Li-Cor Biosciences)] were used at
1:10,000. Blots were visualized using LI-COR Biosciences Odyssey CLx imager.

III.4.4 Developmental timing and egg-laying rate assays
To synchronize worm populations ~15 gravid adult worms were placed into a bleach
solution to release the eggs; hatched worms were raised at 20oC. Four days later, 10
synchronized adults were placed onto a fresh plate and allowed to lay eggs for 1-1.5 hours at
room temperature (22-24oC). Eggs were counted to determine an egg-laying rate; F1 progeny
were placed at 20oC to follow development. After 70-72 hours at 20oC, the developmental stages
of the animals were scored according to their gonadal development and body size. Each
individual trial was performed with at least 3 plates of synchronized eggs for each strain and
always included wild-type animals as a control. For statistical analysis for the egg-laying rate, a
one-way ANOVA with a Tukey or Dunnett post-test (95% confidence intervals) or a chi-square
test was performed to assess similarity between groups and for developmental timing using
GraphPad Prism 8 software.

III.4.5 Viability assays
10 synchronized gravid adults were placed onto a fresh plate and allowed to lay eggs for
2 hours at 20oC. Adult P0 were killed and eggs were counted; F1 progeny were counted after 72
hours. Each individual trial was performed with at least 3 plates of synchronized eggs for each
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strain and always included wild type as a control. For statistical analysis a one-way ANOVA
with Tukey post-test (95% confidence intervals) was performed to assess similarity between
groups using Prism8 software (GraphPad).

III.4.6 RNA interference assays
RNAi by feeding: day 1, a single RNAi clone was picked from the Ahringer RNAi
library (HT115 bacteria, which are maintained at -80oC) and plated onto Luria broth medium
(LB) agar plates (25 μg/ml carbenicillin and 12.5 μg/ml tetracycline) (Kamath et al., 2000)
(Geneservice); day 2, individual colonies were picked from LB agar plates and incubated in 1 ml
LB containing 100 μg/ml ampicillin (at 37°C, 280 rpm) overnight; day 3, 1 ml bacterial culture
was transferred into 10 ml LB containing 100 μg/ml ampicillin and incubated for another 4-6
hours at 37°C at 280 rpm. 450 μl of the bacteria culture was spread onto MYOB plates (Church
et al., 1995) containing 400 mM of β-D-isothiogalactopyranoside (IPTG) and 50 μg/ml
ampicillin and these RNAi plates were placed in 37°C overnight; day 4, eight L4 animals (Po)
were placed on bacteria lawn that expresses double-stranded RNA (dsRNA) of a target gene or
empty vector control (L4440) to knock down expression levels of the targeted gene; day 7, about
50 F1 L4 animals were transferred onto new plates containing the same dsRNA expressing
bacteria; day 10, about 10 F1 one day adults were transferred onto new plates containing the
same dsRNA expressing bacteria and allowed to lay eggs for 1-1.5 hours at 20oC; F2 eggs either
placed at 20oC or at 27oC; day 13, the F2 population was scored for developmental progression
and survival. A dpy-7 RNAi was always done in parallel to ensure that the RNAi plates were
properly made.
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III.4.7 Construction of transgenic lines (From J-S. Yang, personal communication)
To tag the extracellular and cytoplasmic domains of APL-1, we performed overlapping
polymerase chain reaction (PCR). We used an existing apl-1 plasmid apl-1H (Hornsten et al.,
2007) as a template for overlapping PCR to insert the superfolder GFP (sfGFP) in exon 6 of
APL-1 (between K233 and D234), resulting in plasmid APL-1::sfGFP (exon 6). To tag the Cterminus, we performed overlapping PCR with the APL-1::sfGFP (exon 6) plasmid and pCFJ90
(Frøkjaer-Jensen et al., 2008) to insert mCherry (mCh) after the last APL-1 amino acid; the
resultant plasmid was named APL-1::sfGFP (exon 6)::mCh. This construct was microinjected
into lon-2 apl-1(yn10)/dpy-8 heterozygous animals to generate transgenic lines ynEx250 and
ynEx251, both of which had lost the cis lon-2 marker.

III.5 RESULTS
III.5.1 APL-1 is complexed with perlecan/UNC-52
The extracellular fragment, sAPP, binds to several components of the ECM, but the sAPP
receptor has not been unequivocally identified, perhaps because sAPP may bind different
receptors in different contexts. Proposed receptors or binding partners for sAPPα include
GABABR (Rice et al., 2019), insulin receptors (Aulston et al., 2018), and membrane bound
heparan sulfate proteoglycans (HSPGs) (Reinhard et al., 2013). To identify proteins that bind to
sAPL-1, we tagged the extracellular or cytoplasmic domains of APL-1 with green fluorescent
protein (GFP) and performed co-immunoprecipitations using an antiserum that recognizes GFP.
Proteins were isolated from mixed populations of three different strains of C. elegans: wild type
(N2 var. Bristol), apl-1(ynIs79), a transgenic line that carries a transgene expressing a C-terminal
GFP tag, and apl-1(yn10) carrying a rescuing transgene, which contained a super folder (sf) GFP
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tag between the E1 and E2 domains. Protein extracts were incubated with an α-GFP antibody
and complexes were precipitated using agarose beads. Complexed proteins were analyzed using
HPLC-ESI-MS/MS, and their respective peptides were determined using Mascot database search
(Fig. 1); proteins immunoprecipitated with wild type extracts were used as subtractive controls.
Mixed stage animals
lyse
a-GFP
immunoprecipitation
HPLC-ESI-MS/MS

MASCOT

Figure 1. Peptide identification workflow. Proteins were extracted from mixed-stage
populations of wild-type and apl-1(ynIs79) and apl-1(ynEx250 or ynEx251) transgenic animals.
Protein extracts were incubated with anti-GFP and A/G sepharose beads. Immunoprecipitated
proteins were analyzed using HPLC-ESI-MS/MS, and peptides were identified using Mascot
database; wild-type extracts were used as a subtractive control. Number of trials = 3
We identified 40 candidate interacting proteins, 13 of which have not been previously
characterized (Table 1), from the three trials. The majority of the identified proteins were
receptors or receptor-related, suggesting that sAPL-1 may serve as a ligand for these receptors.
The expression pattern for many of these candidate proteins (Wormbase) is consistent with that
for binding to sAPL-1 (Hornsten et al., 2007).
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Table 1. APL-1-Interacting Proteins
Protein
UNC-52
EAT-6
UNC-93
AEX-3
MACO-1
VIT-1
Y44A6C.2
TBC-8
C27D8.2
SNB-5
DAF-1
SRE-13
PDI-2
MORC-1
GCC-2
TAG-341
RPN-12
TBC-9
CDH-3
GLO-4
VPS-33.1
T12B3.3
F36G9.13
VAV-1

Human Ortholog/Description
HSPG2/perlecan
ATPase Na+/K+ transporting unit α3
K+ channel regulator
Rab guanyl-nucleotide exchange factor
TM protein 57
Lipid transporter
Uncharacterized
SGSM1 (small G protein signal modulator)
Uncharacterized
Synaptobrevin related
Predicted TGFβ receptor activity
Uncharacterized
P4HB
MORC1
GolginA1
Rho GTPase activating protein 29
PSMD8
TBC1D8B TBC1D9B. GTPase activator activity and Rab GTPase
binding activity
ProtoCadherin gamma subfamily A, 3
Guanyl-nucleotide exchange factor activity; involved in negative
regulation of axon extension
Related to yeast Vacuolar Protein Sorting factor
Glycerophosphodiester Phosphodiesterase 1, Membrane Interacting
Protein Of RGS16
Uncharacterized
VAV guanine nucleotide exchange factor 1 and 2; predicted to have
Rho guanyl-nucleotide exchange factor activity and metal ion binding
activity; involved in negative regulation of Notch signaling pathway,

Location and/or Function
Basement membrane
Cell membrane
Cell membrane, muscle, nerves
Cytosolic, synaptic transmission
Neuron cell body membrane
Yolk protein
Uncharacterized
Nervous system
Uncharacterized
Uncharacterized
Multiple tissue types
Uncharacterized
Cell membrane
CW-type zinc finger protein, apoptosis
Uncharacterized
Cell membrane
Proteasome subunit
Uncharacterized

Basement membrane neuronal
Axon, synapse, digestive tract, muscle,
nervous system
Several tissue types
Uncharacterized

Germline, males
Digestive, epithelial, nervous, vulva
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T09A5.11
R12B2.6
K02F6.4
UNC-41
GCY-23

positive regulation of locomotion, and regulation of vulval development
Predicted to have transferase activity, transferring glycosyl groups
Uncharacterized
Predicted to encode a protein with the following domains: BRCT,
Ankyrin repeat, WSN
STON1, STON2. Related to components of the endocytic machinery.
Involved in positive regulation of locomotion
NPR1 and NPR2 (natriuretic peptide receptor 1 and 2) are predicted to
have guanylate cyclase activity
PSMD14 (proteasome 26S subunit, non-ATPase 14); predicted to have
metal ion binding activity and metallopeptidase activity
TENM2, TENM3, and TENM4 are involved in organ development,
basement membrane assembly, embryonic body morphogenesis, and
neuron development.
GLRA3 and GLRA4 (glycine receptor alpha) 3 and 4) are predicted to
have chloride channel activity, extracellular ligand-gated ion channel
activity, and transmembrane signaling receptor activity.
ISLR, ISLR2 (immunoglobulin superfamily containing leucine rich
repeat), and LRRN3 (leucine rich repeat neuronal 3) are predicted to
have calcium ion binding activity and catalytic activity. They are
involved in gonad and nervous system development.
7TM GPCR, serpentine receptor class D
GSK3A and GSK3B are predicted to have ATP binding activity and
protein serine/threonine kinase activity. They also play a role in the
WNT and PI3K signaling pathways, as well as regulates the production
of beta-amyloid peptides associated with Alzheimer's disease
Uncharacterized
Calponin homology domain containing protein

RPN-11

W06D11.5
CHDP-1

BYSL (bystin like); human BYSL exhibits RNA binding activity.

SRD-41
R03D7.5

DIG-1

GGR-1

TEN-1

BYN-1

Plasma membrane, endoplasmic reticulum
Coelomocyte, the nervous system, and the
seam cell
Uncharacterized
Synapses

Involved in detection of temperature
stimulus, thermosensory behavior, and
thermotaxis; localizes to the neuron
projection terminus of the AFDL/R neurons
Uncharacterized

Nucleus, plasma membrane, digestive
system, reproductive system, hyp7 precursor
cell
Head, nervous system

Expressed in several tissues, including
muscle
Muscle
Uncharacterized

Uncharacterized
Expressed in multiple tissues including
neurons
Uncharacterized
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FIC-1
AMT-1
GST-1

F46F11.1
LIN-49
LONP-2
ACR-2

FICD, exhibits protein adenylyltransferase activity; involved in defense
response to Gram-negative bacterium and protein adenylylation
Ammonium transmembrane transporter
GSTP1 (glutathione S-transferase pi 1). Shows glutathione transferase
activity; involved in several processes, including defense response to
Gram-negative bacterium, innate immune response, and regulation of
neuron death
PPIP5K2. Predicted to have ATP binding activity and transferase
activity, transferring phosphorus-containing groups
BRD1 (bromodomain containing 1), and BRPF3 (bromodomain and
PHD finger containing 3), predicted to have metal ion binding activity

DYS-1

DMD (dystrophin). Exhibits acetylcholine transmembrane transporter
activity; involved in several processes, including acetylcholine
transport, cholinergic synaptic transmission, and forward locomotion

LONP2 (lon peptidase 2, peroxisomal), predicted to have ATP binding
activity, ATP-dependent peptidase activity, and serine-type
endopeptidase activity
CHRNB1 (cholinergic receptor nicotinic beta 1 subunit), CHRNB2
(cholinergic receptor nicotinic beta 2 subunit), and CHRNB4
(cholinergic receptor nicotinic beta 4 subunit). Exhibits acetylcholinegated cation-selective channel activity; is predicted to contribute to
extracellular ligand-gated ion channel activity; is involved in several
processes, including calcium ion import across plasma membrane,
neuromuscular synaptic transmission, and regulation of gene expression

EMB-5
FER-1

SUPT6H. Predicted to have histone binding activity and nucleosome
binding activity
DYSF (dysferlin); predicted to have calcium-dependent phospholipid
binding activity; involved in several processes, including flagellated
sperm motility, membrane fusion, and plasma membrane organization

Endoplasmic reticulum, nuclear envelope,
and is expressed in multiple tissue types
Uncharacterized
DA neuron

Cytoplasm
Uncharacterized
Uncharacterized

Localizes to neuron projection; expressed in
several tissues, including the nervous system
and the vulval muscles

localizes to the dystrobrevin complex and
striated muscle dense body, body wall
musculature, the pharyngeal muscle cell, and
the vulval muscles
Expressed in the tail

Localizes to several cellular components,
including the integral component of
organelle membrane, integral component of
plasma membrane, and neuronal cell body
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MEI-2
NHR-6

PAR-3

PTP-4
R03D7.4
ZK945.4

Contributes to microtubule-severing ATPase activity; is involved in
embryo development, meiotic spindle organization, and microtubule
depolymerization
NR4A1 (nuclear receptor subfamily 4 group A member 1) and NR4A2
(nuclear receptor subfamily 4 group A member 2); exhibits DNAbinding transcription factor activity and sequence-specific DNA binding
activity; involved in positive regulation of transcription by RNA
polymerase II, regulation of ovulation, and spermathecum
morphogenesis
PARD3 (par-3 family cell polarity regulator) and PARD3B (par3 family cell polarity regulator beta); predicted to have
phosphatidylinositol binding activity; involved in several processes,
including asymmetric cell division, cell adhesion, and establishment of
mitotic spindle orientation
PTPRG (protein tyrosine phosphatase receptor type G) and PTPRZ1
(protein tyrosine phosphatase receptor type Z1) ortholog; predicted to
have protein tyrosine phosphatase activity
ELOA (elongin A) ortholog; involved in transcription elongation from
RNA polymerase II promoter; localizes to the transcription elongation
factor complex
Predicted to have zinc ion binding activity

membrane; is expressed in the male and the
spermatocyte
Localizes to several cellular components,
including the intracellular organelle

Localizes to the nucleus; is expressed in
chemosensory neurons and the spermatheca;

Localizes to the basal part of cell, cytoplasm,
and integral component of membrane; is
expressed in the AB, the excretory cell, the
germline blastomere, and the reproductive
system
Uncharacterized
Uncharacterized
Uncharacterized
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III.5.2 Loss of perlecan/UNC-52 compromises viability in apl-1(yn5) mutants
To determine whether there is an interaction between APL-1 and the candidate proteins
identified by MS analysis, we used RNAi to knockdown the expression levels for each candidate
in either a wild-type, apl-1(yn5) mutant, or apl-1(ynIs79) transgenic background. The apl-1(yn5)
mutant is viable and contains a deletion that removes the coding regions for the transmembrane
and cytoplasmic domains; only the extracellular domain is produced and constitutively released
in apl-1(yn5) mutants (Hornsten et al., 2007). The apl-1(ynIs79) animals carry a transgene that
encodes a C-terminal GFP-tagged APL-1 under the regulatory control of the apl-1 promoter.
The yn5 mutants and the ynIs79 animals produce high levels of the extracellular domain of APL1 or APL-1::GFP, respectively (Hornsten et al., 2007). We examined egg-laying rates (Fig. 2,
embryonic development (Fig. 3), and developmental progression (Fig. 4) of knockdowns of
identified interactors.
Wild type animals lay 7.3 ± 0.3 eggs per hour at 20oC; both apl-1(yn5) mutants (4.3 ± 0.2
eggs per hour) and apl-1(ynIs79) transgenic animals (4.5 ± 0.3 eggs per hour) lay significantly
fewer eggs that wild type (Ewald et al., 2012a). Among the candidate interactor genes,
knockdown of several candidate interactor genes enhanced or further decreased the egg-laying
rates in an apl-1(yn5 or ynIs79) background (Table S1). Specifically, knockdown of unc-93,
which encodes a potassium channel regulator, and eat-6, which encodes a sodium/potassium
ATPase, in apl-1(yn5 and ynIs79) animals resulted in fewer eggs than were laid by wild type and
the L4440 controls (Fig. 2; Table S1), suggesting that unc-93 and eat-6 interact with APL-1 in
affecting egg-laying rates. Knockdown of five genes, vit-1/vitellogenin, snb-5/synaptobrevinrelated, gcy-23/receptor guanylate cyclase, R03D7.5 (uncharacterized), and morc-1/MORC zinc
finger, showed lower egg-laying rates compared to apl-1(yn79) only, while knockdown of the
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dig-1/Ig superfamily showed lower rates compared to only apl-1(yn5) mutants (Fig. 2; Table S1).
By contrast, two knockdowns, vav-1/guanine nucleotide exchange factor (GEF) and
T09A5.11/glycosyl transferase, increased the egg-laying rates in an apl-1(yn5 and ynIs79)
background compared to wild type. In several knockdowns, tbc-9/Rab GAP, F36G9.13,
K02F6.4, W06D11.5, and chdp-1/calponin, the egg-laying rate in an apl-1(yn5) background was
higher than wild type. These data suggest that APL-1 interacts with multiple proteins in the egglaying pathway, and some of these interactions require membrane-tethered APL-1, while others
require soluble APL-1.

Figure 2. The egg laying rates of candidate interactors are affected by APL-1 levels. 5 day
1 adults were allowed to lay eggs for 2 hours on bacteria containing RNAi constructs targeting
individual candidate genes. The number of eggs was counted. Each bar represents the average
number of eggs laid per hour in 2 trials; each data point represents 5 animals.
To determine whether any candidate interactor genes impacted viability, we knocked
down candidate genes in an apl-1(yn5 or ynIs79) background and scored the viability of eggs
laid (Fig. 3; Table S2). Several genes whose knockdown affected egg-laying rates also showed
effects on viability. For instance, knockdown of vav-1/GEF and T09A5.11/glycosyl transferase,
which increased egg-laying rates (Table S1), showed a decreased number of viable eggs in apl112

1(yn5 and ynIs79) backgrounds, suggesting that GDP to GTP exchange or transfer of a sugar
moiety is important for apl-1 function. Knockdown of unc-52/perlecan, gcc-2/Golgin A1, and
dig-1/Ig superfamily showed similar viability as wild type, but showed higher rates of lethality in
an apl-1(yn5) background (Fig. 3; Table S2). eat-6/ Na+/K+ ATPase, aex-3/Rab guanylnucleotide exchange factor (RabGEF), tbc-9/Rab GTPase activating protein (RabGAP),
W06D11.5, and byn-1/BYSL knockdowns showed differences in apl-1(ynIs79) viability as
compared to wild-type (Fig. 3, Table S2). Knockdown of many of these genes also affected egglaying rates (Fig. 2; Table S1), suggesting that membrane-associated APL-1, and sAPL interact
with exchange factors to trigger cascades that influence egg-laying and embryonic development,
in an APL-1 concentration dependent manner.

Figure 3. APL-1 levels affect the embryonic viability when candidate genes are knocked
down. Eggs from day 1 adults, in which candidate genes were knocked down by RNAi feeding,
were allowed to develop for 24 hours. After 24 hours, unhatched eggs were quantified. Each bar
represents the average fraction of unhatched eggs for 2 trials; each data point represents 5
animals.
Wild-type animals develop from eggs to adults in ~72 hours at 20oC (Bustos and
Partridge, 2017). apl-1(yn5) mutants have a slowed developmental progression, as do animals
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that overexpress apl-1 (Ewald et al., 2012b; Hornsten et al., 2007). To determine whether any
candidate interactors affect development, we scored the candidates for developmental
progression in wild-type and apl-1(yn5 and ynIs79) backgrounds (Fig. 4; Table S3). Several
candidate interactor genes affected developmental progression. Knockdown of several genes
caused a developmental delay. For instance, knockdown of eat-6/Na+/K+ ATPase alone caused a
developmental delay: most animals were in their fourth larval stage rather than adults (Fig. 4;
Table S3). This delay was enhanced in apl-1(ynIs79) animals by at least one larval stage,
whereas in an apl-1(yn5) mutant background, the developmental delay was severely enhanced:
>90% of that animals were arrested at the first or second larval stage. Similarly, when unc52/perlecan or rpn-12/PSMD8, a proteosome regulatory particle, was knocked down in an apl1(yn5) background, no adults were seen; instead, most animals were in the fourth larval stage
(rpn-12) or had not reached the fourth larval stage and 60% were arrested at the L1 to L2 stage
(unc-52). These results suggest that APL-1 functions with UNC-52/perlecan and EAT-6/Na+/K+
ATPase during development and that high levels of APL-1 inhibits developmental progression.
There were also several genes whose knockdown enhanced the developmental progression of
apl-1(yn5 or ynIs79) animals. Knockdown of F36G9.13, which encodes a protein of unknown
function, caused all apl-1(yn5) mutants and most apl-1(ynIs79) animals to progress to a later
adult stage. Other knockdowns, such as cdh-3/protocadherin, vps-33.1/vacuolar protein sorting
receptor, and unc-41/STON2, accelerated the development of apl-1(yn5) mutants, such that most
animals were egg-laying adults. Knockdown of gcy-23/NPR1/2 and K02F6.4 suppressed the
lethality associated with apl-1 overexpression and all animals proceeded to become egg-laying
adults. Overall, APL-1 interacts with many proteins to regulate developmental progression.
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Figure 4. Knockdown of different candidates affects developmental progression. Each
candidates gene was knocked down by RNAi in wild type and apl-1(yn5 and ynIs79) mutants.
Animals were allowed to develop for 72 hours and the number of animals at each developmental
stage was tallied. Each bar represents the total percentage of animals at a particular
developmental stage over the course of 2 trials; N=number of animals scored.
III.5.3 The apl-1(yn5) mutation enhanced the defects in unc-52/perlecan mutants
Because UNC-52 knockdown severely impaired apl-1(yn5) development (Fig. 4), and in
mammals, HSPGs interact with mammalian APP (Reinhard et al., 2013; Small et al., 1996), we
chose to further examine the interaction between APL-1 and UNC-52/perlecan. UNC-

116

52/perlecan is required for proper sarcomere construction and myofilament attachment to the
body wall muscle cells (Mackenzie et al., 1978). Loss of unc-52 results in embryonic lethality,
while partial loss of function alleles result in progressive paralysis (Gilchrist and Moerman,
1992; Rogalski et al., 1993). Knockdown of unc-52/perlecan by RNAi caused paralysis in
31.3% of day 1 adults (Fig. 5; Table S4). However, when unc-52 was knocked down in apl1(yn5) mutants, 98.9% of apl-1(yn5) mutants were paralyzed and unable to produce viable
progeny (Fig. 5; Table S4), similar to what is seen in unc-52 null alleles. By contrast,
knockdown of unc-52 in wild type and apl-1(ynIs79) animals did not affect the rate of paralysis
or their ability to produce viable progeny.

Figure 5. The apl-1(yn5) mutation enhances the paralysis of unc-52 mutants. unc-52 was
knocked down in wild type and apl-1(yn5 and ynIs79) mutants by RNAi feeding. Number of
paralyzed animals was counted after 72 hours. Each data point represents 5 P0s, whose offspring
were scored. One-way ANOVA, Dunnett’s post test. ****p<0.0001. Number of trials=3,
N=number of animals scored.
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III.5.4 APL-1 co-precipitates with UNC-52/perlecan
The behavioral data suggest physiological interactions between apl-1 and unc-52. To
determine whether there is a physical association between UNC-52 and APL-1 proteins, we
examined whether the two proteins could co-immunoprecipitate. We incubated protein extracts
from wild type, apl-1(yn5 and ynIs79) animals with an anti-UNC-52/perlecan antibody and coimmunoprecipitated the protein complex for Western blotting. The co-immunoprecipitated
complex contained APL-1, indicating that the proteins are present together minimally in a
complex (Fig. 6).

Figure 6. APL-1 is in a complex with UNC-52. Protein extracts from wild type, apl-1(ynIs79)
and apl-(ynEx201) animals were co-immunoprecipitated with anti-UNC-52 antisera and probed
with anti-APL-1 antisera. Number of replicates= 3
III.6 DISCUSSION
Like loss of the mammalian APP family, complete loss of apl-1 causes a 100% penetrant
lethality (Heber et al., 2000; Hornsten et al., 2007; von Koch et al., 1997). We have shown for
the first time in an in vivo context that there is an interaction between APL-1 and UNC52/perlecan. Our findings are consistent with crystallography data pointing to heparin binding
sites in APL-1/APP family in the E1 and E2 domains (Dulubova et al., 2004; Hoopes et al.,
2010; Keil et al., 2004; Wang and Ha, 2004). Furthermore, Reinhard and co-workers (2013)
found that sAPP-HSPG binding to the core PG occurred in the absence of heparin and HS
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modifications. We are, therefore, uncertain as to whether our detected interaction is mediated by
heparin, HS, or sAPL-1 binding directly to the PG.
We showed that the UNC-52-APL-1 interaction is necessary early in development. We
suggest that UNC-52/perlecan may be required to spatially localize sAPL-1 after its release to
enable its function as a ligand (Fig. 7). The APP family has characteristics that are typical of
growth factors. Some similarities are that growth factors are single-pass transmembrane proteins
that shed their ectodomain, which in turn go on to promote, for example, neurite outgrowth
(reviewed in Chirgadze et al., 1998; Kadomatsu and Muramatsu, 2004); growth factors often
dimerize in the presence of heparin (Mohammadi et al., 2005). Likewise, APP family/APL-1
cleavages are necessary for APL-1/APP functioning (Levy-Lahad et al., 1995; Rogaev et al.,
1995; Sherrington et al., 1995), they are able to bind heparin, and importantly, their ectodomains
contain a growth factor like region (GFLD). These observations suggest that pericellular UNC52/perlecan might help to sequester, deliver, and retain proximity between sAPL-1/sAPP family
and its receptor or co-ligand, thereby facilitating downstream signaling upon receptor binding
(Fig. 7).
In addition to identifying UNC-52/perlecan as an APL-1 binding partner, our list of
identified candidates highlights other possible interacting partners/receptors, which require
deeper analyses to establish their relationship. In addition to its importance in development and
viability, APL-1 impacts myriad other physiological functions, including longevity, mechanoand chemosensations, and memory (Ewald et al., 2012a, b, 2016), all of which have an identified
associated pathway, but unidentified direct receptors.
Our list highlights candidate receptors to examine further. We believe our study is
reliable because we identified proteins implicated in modulating APP processing and
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functioning. For instance APL-1 is internalized by neurons and co-localizes in endosomes with
RAB-5 (Wiese et al. 2010), an endocytosis regulator (Bucci et al., 1992; Grant and Hirsh, 1999).
In addition, vacuole-associated proteins, such as VPS-33.1/VPS33A, which is required for
autophagosome-lysosome fusion (Zhen and Li, 2015), and UNC-41/STON2, which is
downregulated in Alzheimer’s disease and is a component of the endocytic machinery (Bossers
et al., 2010), may participate in regulating levels of the APL-1/APP family. Both autophagy and
endocytosis have been linked to APP/APLP1 recycling (Wang et al., 2018; Zhou et al., 2011).
Additionally in mammals, GSK3B downregulate ADAM and presenilin activity, thereby
decreasing the rate of APP cleavage (reviewed in Llorens-Marítin et al. 2014). We propose that
the ortholog R03D7.5 could perform a similar function in C. elegans.
Mammalian models identified syndecans, glypicans (Reinhard et al., 2013), and
pericellular agrin (Choi et al., 2013) as APP family interacting partners. Here, we show that
UNC-52/perlecan, which most closely resembles AGR-1/agrin in that they are not tethered to the
cell membrane, functions as an sAPL-1 interacting partner, adding another layer of complexity to
APL-1/APP functioning. Our data also suggest a role for the interaction between EAT-6/Na+/K+
ATPase and APL-1. In addition to functioning to maintain membrane potential (Davis et al.,
1995), EAT-6/Na+/K+ ATPase contributes to localization of nicotinic acetylcholine receptors
(nAChRs) to neuromuscular junctions (Doi and Iwasaki, 2008). Vesicular/membrane bound
APL-1 may work in concert with EAT-6 to ensure the accurate placement of nAChRs, by
binding ACR-2/CHRNB1/2/3/4, nAChR subunits, also identified in our immuno-precipitation
study. On the other hand, Choi et al. (2013) showed that agrin interacts with the APP family of
proteins, muscle–associated receptor tyrosine kinase, MuSK, and the APOE receptor, LRP4, to
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cluster AChRs to neuromuscular junctions. APL-1 may, therefore, interact with HSPGs to
localize sAPL-1 diffusion as well as aggregate both types of AChRs to specific locations.

Figure 7. Model describing interaction between APL-1 and UNC-52, and other candidate
proteins. UNC-52 may be responsible for delivering sAPL-1 to membrane receptors/transporters
(e.g, EAT-6, UNC-41, VIT-1, GCY-23, VPS-33.1) on neighboring cells. APL-1 sequestration
may also be necessary for activating molecular switches (e.g., VAV-1 AEX-3, TBC-9, K02F6.4)
to initiate signaling pathways responsible for egg-laying, viability, and developmental
progression. EFs= exchange factors.
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III.8 SUPPLEMENT
Table S1. The egg laying rates of candidate interactors are affected by APL-1 levels
Total
Strain
Total number
RNAi
number
(genotype)
of P0 used
of trials
2
10
L4440
2
10
2
10
2
10
apl-1 APP
2
10
2
10
2
10
unc-52 perlecan
2
10
2
10
2
10
eat-6 Na+/K+ ATPase
2
10
2
10
2
10
unc-93 K+ channel regulator2
2
10
2
10
2
10
aex-3 Rab guanyl-nucleotide exchange factor2
2
10
2
10
2
10
maco-1 TM protein 57
2
10
2
10
2
10
vit-1 lipid transporter
2
10
2
10
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)

Average
number eggs
8.46
6.64
6.00
5.47
4.24
5.23
9.07
6.40
5.67
7.10
3.70
4.17
8.34
3.44
4.43
8.80
5.47
5.20
6.04
3.77
5.57
8.70
6.07
3.50
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Y44A6C.2

tbc-8 SGSM1 small G protein signal modulator

C27D8.2
snb-5 synaptobrevin related2

daf-1 TGFβ receptor activity

sre-13 GPCR

pdi-2 P4HB

morc-1 MORC1

gcc-2 GolginA1

tag-341 rho GTPase activating protein 29

wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10

5.07
4.23
2.93
6.23
5.14
3.97
4.40
3.47
4.30
6.94
5.60
3.03
7.60
5.82
6.14
5.90
3.57
4.47
8.77
6.80
6.10
7.80
7.34
3.20
3.45
2.80
3.15
4.00
5.00
5.10
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rpn-12 PSMD8

tbc-9 TBC1D9 Rab GAP

cdh-3 protocadherin

glo-4 guanyl-nucleotide exchange factor

vps-33.1 vacuolar protein sorting factor

T12B3.3 glycerophoshodiester phosphodiesterase I

F36G9.13

vav-1 VAV guanine nucleotide exchange factor

T09A5.11 glycosyl transferase

R12B2.6

wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10

7.30
5.80
5.40
6.05
7.15
4.85
5.56
3.35
3.85
7.15
5.95
5.85
6.30
4.35
6.45
5.60
5.80
5.35
4.20
5.75
3.90
5.85
6.60
6.00
2.60
5.25
4.35
5.40
6.05
3.65
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K02F6.4

unc-41 STON1/2
gcy-23 NPR1/22

rpn-11 PSMD14

ten-1 TENM2/3/4

ggr-1 GLRA3/4

dig-1 ISLR/2

srd-41 GPCR

R03D7.5 GSK3A/3B

W06D11.5

wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10

7.60
8.10
5.30
6.15
5.85
5.65
10.65
8.15
6.45
4.45
2.85
2.10
8.45
6.70
6.90
7.70
6.55
7.40
7.57
3.57
6.00
5.60
4.27
5.00
8.25
5.44
4.57
4.17
5.27
3.54
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wild type
2
10
4.30
chdp-1 calponin
apl-1(yn5)
2
10
5.23
apl-1(ynIs79)
2
10
4.00
wild type
2
10
3.47
byn-1 BYSL
apl-1(yn5)
2
10
2.47
apl-1(ynIs79)
2
10
2.70
Five animals were plated to each plate and the overall number of eggs was counted before determining an egg laying rate per animal.
1
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wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

Table S2. APL-1 levels affect the embryonic viability when candidate genes are knocked down
Total
Total number
Strain
Total number
number of
unhatched
RNAi
(genotype)
of trials
eggs1
eggs1
253
1
L4440
199
0
180
0
164
0
apl-1 APP
127
0
157
2
272
4
unc-52 perlecan
192
22
170
3
213
1
eat-6 Na+/K+ ATPase
111
0
125
5
149
0
unc-93 K+ channel regulator
103
1
133
1
264
2
aex-3 Rab guanyl-nucleotide exchange
164
1
factor
156
7
181
3
maco-1 TM protein 57
113
0
167
4
261
0
vit-1 lipid transporter
182
1
105
0
152
0
112
3
88
2
Y44A6C.2

Average
fraction
unhatched eggs
0.005
0.000
0.000
0.000
0.000
0.010
0.015
0.110
0.015
0.005
0.000
0.035
0.000
0.010
0.010
0.010
0.005
0.050
0.015
0.000
0.025
0.000
0.005
0.000
0.000
0.030
0.025
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tbc-8 SGSM1 small G protein signal
modulator
C27D8.2

snb-5 synaptobrevin related

daf-1 TGFβ receptor activity

sre-13 GPCR

pdi-2 P4HB

morc-1 MORC1

gcc-2 GolginA1

tag-341 rho GTPase activating protein 29

rpn-12 PSMD8

wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

187
154
119
132
104
129
208
168
91
228
175
184
177
107
134
263
204
183
234
220
96
69
56
63
80
100
102
146
116
108

2
0
2
0
0
0
5
0
3
1
0
1
2
0
2
2
2
0
1
0
0
0
5
0
1
0
1
3
0
0

0.010
0.000
0.020
0.000
0.000
0.000
0.025
0.000
0.025
0.005
0.000
0.005
0.010
0.000
0.010
0.010
0.010
0.000
0.005
0.000
0.000
0.000
0.070
0.000
0.010
0.000
0.010
0.020
0.000
0.000
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tbc-9 TBC1D9 Rab GAP

cdh-3 protocadherin

glo-4 guanyl-nucleotide exchange factor

vps-33.1 vacuolar protein sorting factor
T12B3.3 glycerophoshodiester
phosphodiesterase I
F36G9.13
vav-1 VAV guanine nucleotide exchange
factor
T09A5.11 glycosyl transferase

R12B2.6

K02F6.4

wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

121
143
97
111
67
77
143
119
117
126
87
129
112
116
107
84
115
78
117
132
120
52
105
87
118
121
73
152
162
106

0
1
6
0
0
1
2
2
1
1
1
0
0
0
8
2
1
2
0
5
1
1
9
8
0
1
0
0
0
0

0.000
0.005
0.065
0.000
0.000
0.005
0.010
0.015
0.010
0.010
0.010
0.000
0.000
0.000
0.075
0.025
0.010
0.020
0.000
0.040
0.010
0.020
0.095
0.125
0.000
0.010
0.000
0.000
0.000
0.000

130

unc-41 STON1/2

gcy-23 NPR1/2

rpn-11 PSMD14

ten-1 TENM2/3/4

ggr-1 GLRA3/4

dig-1 ISLR/2

srd-41 GPCR

R03D7.5 GSK3A/3B

W06D11.5

chdp-1 calponin

wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

123
117
113
213
163
129
89
57
42
169
134
138
154
131
148
227
107
180
168
128
150
248
163
137
125
158
106
129
157
120

0
0
0
3
4
1
81
57
40
1
0
1
0
0
0
0
2
0
1
1
2
0
1
0
3
2
7
0
0
3

0.000
0.000
0.000
0.010
0.020
0.015
0.910
1.000
0.940
0.005
0.000
0.005
0.000
0.000
0.000
0.000
0.020
0.000
0.005
0.010
0.010
0.000
0.005
0.000
0.025
0.015
0.080
0.000
0.000
0.025
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wild type
2
104
2
0.020
byn-1 BYSL
apl-1(yn5)
2
74
0
0.000
apl-1(ynIs79)
2
81
5
0.135
1
Five animals were plated and allowed to lay eggs for 2 hours. 24 hours later, the number of unhatched eggs were counted and the
number of unhatched eggs/animal calculated.
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RNAi1

wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)

199

252

0

33
164
46
45
172
130
36
212
48
20

0
48
(100%)
11
(55.0%)

0
43
(93.5%)
12
(26.7%)
27
(15.7%)
79
(60.8%)
16
(44.4%)

0
12
(36.4%)

Table S3. Knockdown of different candidates affects developmental progression
Strain
Total
L1-L3
(genotype)

L4440

apl-1 APP

unc-52 perlecan

eat-6 Na+/K+ ATPase

apl-1(ynIs79)

0

0
4
(2.4%)
1
(2.2%)

4
(1.6%)
88
(44.2%)

0

0

0
2
(4.3%)

0
111
(55.8%)

Young
Adults

0

0

L4

51
(39.2%)

0

20
(55.6%)
13
(6.1%)

Egg-laying
Adults
248
(98.4%)

0

9
(4.3%)

0
2
(10.0%)

0

190
(89.6%)

0
2
(10.0%)

0

0
33
(73.3%)
145
(84.3%)

0
21
(63.6%)
160
(97.6%)

0
5
(25.0%)
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unc-93 K+ channel regulator

aex-3 Rab guanyl-nucleotide exchange factor

maco-1 TM protein 57

vit-1 lipid transporter

Y44A6C.2

wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)

163

262

30

102

250

0

0

0

0
11
(36.7%)

0

181

0
5
(4.9%)

0

0

0

0
38
(33.6%)

0
1
(0.6%)

0

0

22

0
97
(95.1%)
1
(3.3%)
4
(1.5%)
162
(99.4%)
10
(45.5%)
apl-1(ynIs79)
wild type
apl-1(yn5)
apl-1(ynIs79)
wild type
apl-1(yn5)

0

0
30
(16.6%)
2
(28.6%)
apl-1(ynIs79)

178

0
75
(66.4%)
7
(18.4%)
5
(2.2%)
151
(83.4%)
1
(14.3%)

0

0

0
4
(57.1%)

0

113

7

0

38

152

0

0
1
(0.4%)

wild type

109

4
(36.4%)

230

apl-1(yn5)

11

13
(11.9%)
2
(18.2%)
apl-1(ynIs79)

250
(100%)

0
18
(60.0%)
258
(98.5%)

0
12
(54.5%)
178
(100%)

0
31
(81.6%)
224
(97.4%)

0

0
152
(100%)
96
(88.1%)
5
(45.4%)
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tbc-8 SGSM1 small G protein signal modulator

C27D8.2

snb-5 synaptobrevin related

daf-1 TGFb receptor activity

sre-13 GPCR

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

107

175

35

175

229

10

168

203

30

104

132

26

154

185

12
(50.0%)

0

0

8
(22.9)

0

0

4
(40.0%)

0

0

1
(3.3%)

0

0

13
(50.0%)

0

0

0

78
(72.9%)

0

0

1
(0.4%)
75
(42.9%)

0

17
(10.1%)

0

1
(0.8%)
24
(23.0%)
3
(10.0%)

0

7
(4.5%)

0

0

29
(27.1%)

0

0

100
(57.1%)

0

0

0

79
(76.0%)

0

147
(95.5%)

0

12
(50.0%)

0

0

185
(100%)

0

0

0

apl-1(yn5)

24

27
(77.1%)
175
(100%)

0

13
(50.0%)
131
(99.2%)
1
(1.0%)
26
(86.7%)
203
(100%)
151
(89.9%)
6
(60.0%)
228
(99.6%)

apl-1(ynIs79)
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pdi-2 P4HB

morc-1 MORC1

gcc-2 GolginA1

tag-341 rho GTPase activating protein 29

rpn-12 PSMD8

wild type
202

263

200
(99.0%)
2
(4%)

0

70
(26.6%)
2
(1.0%)
17
(34%)

216
(96.9)

0

3
(1.2%)

apl-1(yn5)
50

0

7
(3.1%)

0

190
(72.2%)

apl-1(ynIs79)

233

0

0

0

0

wild type

223

7
(21.9%)

0

0

apl-1(yn5)

32

0

8
(15.7%)

43
(84.3%)
12
(100%)

0

apl-1(ynIs79)

69

0

0

0

wild type

51

0

0

0

25
(78.1%)
69
(100%)

0

0

0

5
(17.9%)

0

17
(94.4%)
143
(100%)

0

0

31
(62%)
233
(100%)

apl-1(yn5)

12

apl-1(ynIs79)

79
(100%)
79

0

0

wild type

100

0

116
(100%)
11
(39.2%)

0

0
apl-1(yn5)

18

0

0

apl-1(ynIs79)

143

0

0

wild type

116

12
(42.9%)

79
(79.0%)

apl-1(yn5)

28

21
(21.0%)
1
(5.6%)

apl-1(ynIs79)
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tbc-9 TBC1D9 Rab GTPase

cdh-3 protocadherin

glo-4 guanyl-nucleotide exchange factor

vps-33.1 vacuolar protein sorting factor

T12B3.3 glycerophoshodiester phosphodiesterase I

apl-1(yn5)

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

33

116

112

17

86

126

9

117

141

24

60

111

23

142

121

8
(24.2%)

0

0

3
(3.5%)
1
(7.0%)

0

5
(55.6%)

0

0

7
(29.2%)

0

0

22
(95.7%)

0

0

0

58
(50.0%)

0

6
(7.0%)
3
(17.6%)

0

54
(46.2%)
1
(11.1%)

0

0

3
(5.0%)

0

0

141
(99.3%)

0

0

3
(2.6%)

0

0

63
(53.8%)
3
(33.3%)

0

0

0

0

0

121
(100%)
1
(0.7%)

0

0

apl-1(ynIs79)

0

0

1
(4.3%)
111
(100%)
57
(95.0%)
17
(70.8%)
141
(100%)

0

0

126
(100%)
77
(89.5%)
13
(76.4%)
112
(100%)
55
(47.4%)
25
(75.8%)

137

F36G9.13

vav-1 VAV guanine nucleotide exchange factor

T09A5.11 glycosyl transferase

R12B2.6

K02F6.4

apl-1(ynIs79)

apl-1(yn5)

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

152

22

120

108

8

18

8

42

127

117

17

114

82

0

0

6
(27.3%)

0

0

19
(45.2%)
6
(75%)
18
(100%)
6
(75%)

0

0

1
(5.9%)

0

0

0

11
(6.8%)

0

68
(56.7%)
7
(31.8%)

0

1
(12.5%)

0

109
(85.8%)

0

2
(11.8%)

0

0

0

57
(35.2%)

0

52
(43.3%)
2
(9.1%)

0

1
(12.5%)

0

18
(14.2%)
6
(14.3%)
2
(25%)

0

0

0

0

108
(100%)

0

0

82
(100%)
114
(100%)
14
(82.3%)
117
(100%)

wild type

162

0

0

7
(31.8%)
152
(100%)
94
(58.0%)
18
(100%)

0

0

17
(40.5%)

0

apl-1(yn5)

18

0

apl-1(ynIs79)

138

unc-41 STON1/2

gcy-23 NPR1/2

rpn-11 PSMD141

ten-1 TENM2/3/4

ggr-1 GLRA3/4

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

apl-1(yn5)
apl-1(ynIs79)

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

131

154

40

134

168

0
0

3

128

163

210

13

117

123

0

0

0

21
(52.2%)

0

0

3
(100%)
0
0

0

0

0

3
(23.1%)

0

0

0

131
(100%)

0

0

131
(97.8%)

0

0
0

0

0

151
(92.6%)

0

2
(15.9%)

0

0

148
(100%)

0

0

3
(2.2%)
19
(47.5%)

0

0
0

0

0

12
(7.4%)

0

0

0

0

0

0

154
(100%)

0
0
168
(100%)

0

128
(100%)

0

123
(100%)
117
(100%)
8
(61.5%)
210
(100%)

apl-1(yn5)

148

0

0

apl-1(ynIs79)
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dig-1 ISLR/22

srd-41 GPCR

R03D7.5 GSK3A/3B

W06D11.5

chdp-1 calponin

apl-1(ynIs79)

apl-1(yn5)

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

apl-1(ynIs79)

apl-1(yn5)

wild type

129

26

156

122

46

180

248

37

127

167

47

97

227

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

157
(100%)

0

0

143
(91.7%)

0

0

160
(88.9%)

0

0

63
(49.6%)

0

0

80
(82.5%)

0

20
(71.4%)

0

0

227
(100%)
0

wild type

157

8
(28.6%)

13
(8.3%)
14
(53.8%)

0

20
(11.1%)
16
(34.8%)

0

17
(17.5%)
22
(46.8%)
1
(0.6%)
11
(8.7%)
18
(48.6%)

apl-1(yn5)

28

12
(46.2%)
129
(100%)

0

30
(65.2%)
122
(100%)

0

25
(53.2%)
166
(99.4%)
53
(41.7%)
19
(51.4%)
248
(100%)

apl-1(ynIs79)

140

1

29
wild type
102
0
(28.4%)
21
byn-1 BYSL
apl-1(yn5)
51
0
(41.2%)
12
apl-1(ynIs79)
18
0
(66.7%)
Candidate genes were knocked down by RNAi in wild type, apl-1(yn5) and apl-1(ynIs79) backgrounds.

0
30
(58.8%)
6
(33.3%)

73
(71.6%)

0

0

141

Table S4. The apl-1(yn5) mutation enhances the paralysis of unc-52 mutants
Total
Total
Total
[Fraction paralyzed
Strain
number of number
number
± SEM] x 100
(genotype)
trials
F1s
paralyzed
wild type
3
438
137
31.33 ± 6.59
apl-1(yn5)
3
278
275
98.91 ± 0.80****
ynIs79
3
201
36
17.84 ± 4.40
unc-52 was knocked down by RNAi feeding in wild type and apl-1(yn5 and ynIs79) mutants. One-way ANOVA, Dunnett’s post hoc
test. ****p<0.0001 significantly different from wild type.
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Chapter IV
Discussion and future directions
IV.1 Discussion and future directions
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects 5.8
million Americans (Gaugler et al., 2019). Postmortem studies of AD patients’ brains reveal two
major consistencies: 1) intracellular neuronal tangles derived from tau protein; and 2)
extracellular β- amyloid (Aβ) plaques derived from sequential cleavages of the amyloid
precursor protein, APP (Kidd, 1964; Krigman et al., 1965; Luse and Smith, 1964; Terry et al.,
1964). There is a strong correlation between the pathogenesis of AD and the mutations in APP
and proteins that process APP to generate the Aβ peptide. However, this correlation only exists
in approximately 10% of patients, and is categorized as ‘familial’ AD due to its heritable nature,
and ‘early-onset’ because afflicted patients are <65 years old (Gaugler et al., 2019). By contrast,
90% of AD cases occur sporadically with no clear inheritance pattern; obvious symptoms occur
>65 years old; hence, this form of AD is termed ‘late-onset’ (Gaugler et al., 2019).
There is no cure for AD. Despite the research efforts and monetary resources devoted to
AD, researchers do not yet fully understand the normal function of APP and its contribution to
late-onset AD. Using mammalian models to study APP has proven to be complicated because
APP belongs to a family of genes with overlapping functions. Knockout of the APP family leads
to lethality, while knockouts of single family members do not present severe phenotypes (Heber
et al., 2000; von Koch et al., 1997). Neuronal sAPPα knockin is sufficient to rescue the lethality
associated with the APP gene family knock out (Weyer et al., 2011). Interestingly, pivotal work
done using the simpler model organism, C. elegans, informed mammalian researchers that the
extracellular APP fragment was sufficient for viability (Hornsten et al., 2007), and many of the
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presenilin components were first identified in C. elegans (Jarriault and Greenwald, 2005; Levitan
and Greenwald, 1995; Link, 2006). Consequently, we hope that our recent findings continue to
advance our understanding of the normal function of APP, and provide insights into the events
leading to AD.
Here, we outlined biochemical and genetic approaches to identifying APL-1/APP
interacting partners. By using GFP-tagged-APL-1, we identified approximately 40 APL-1
interacting partners. We believe that many of these interactions may be transient, weak,
developmental stage specific, or based on environmental conditions because different iterations
of our IPs yielded slight differences in the identity of precipitated proteins. Future studies must,
therefore, include synchronous worm populations and protein samplings from specified
developmental time points. Our genetic approach in which we mutagenized apl-1(yn5) mutants,
yielded 2 mutants that suppressed the apl-1 RNAi lethality in the apl-1(yn5) background. RNAi
analysis of these candidate genes allowed us to narrow our focus on two possibilities.
Knockdown by RNAi feeding of several of our candidate genes from both our
biochemical and genetic approaches in sensitized apl-1 backgrounds (yn5, yn10 and ynIs79)
yielded no obvious phenotypes. We attribute this to knockdowns not being as effective as
knockouts, and the observation that several neuronal genes are not susceptible to knock down by
RNAi feeding (Simmer et al., 2002). Candidate genes should be re-screened by acquiring null
mutants and assessing their impacts in different apl-1 mutant backgrounds. In addition to
examining knockdown effects of candidate genes, we should also look at other parameters, based
on categories in which different candidates belong (Chapter 3. Table 1). For example,
appropriate experiments should be conducted to assess perturbations in channel conductance,
vacuolar sorting, G-protein coupled serpentine proteins, calcium ion binding, and signaling
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cascades, just to name a few. We expect that disruption of candidate genes such as acr2/CHRNB1, dys-1/DMD, and ggr-1/GLRA3/4 will highlight APL-1/APP family involvement in
synaptic transmission, and response to certain stimuli; studying unc-41/STON1/2 and vps33.1/VPS33A will give more insights to APL-1/APP trafficking both into and out of cells; and
tbc-8/SGSM1, tbc-9/TBC1D8B/9B mutant studies will shed light on uncharacterized 7TMs to
which APL-1/APP binding may trigger signaling cascades and alter gene transcription.
Nevertheless, we identified UNC-52/perlecan as an APL-1 interacting partner. Our work
potentially reveals that APP’s interaction with HSPGs are not limited to syndecans, glypicans
and agrin but rather, APP may interact with all HSPGs (Choi et al., 2013; Reinhard et al., 2013).
Domain analysis should be conducted to determine which regions of APL-1 and UNC-52 are
necessary for their interaction, and microscopy should be used to determine the tissues in which
APL-1-UNC-52 foci are present.
Our biochemical approach also revealed EAT-6/Na+/K+ ATPase as an APL-1 binding
partner. In mammals, one function of Na+/K+ ATPase is to localize nAChRs to neuromuscular
junctions (Doi and Iwasaki, 2008); similarly, agrin interacts with a complex comprising APP,
MuSK, and LRP4 to localize AChRs to neuromuscular junctions (Choi et al., 2013). We
speculate that an UNC-52/perlecan-APL-1/APP-EAT-6/Na+/K+ ATPase complex mediates
nAChRs localization to neuromuscular junctions. We intend to investigate this hypothesis
further by disrupting this complex, observing changes in receptor localization, and measuring
resulting changes in locomotion.
The candidate list generated from our biochemical approach did not overlap with that of
our genetic approach, emphasizing the complex and myriad relationships involving APL-1/APP
family. From our genetic approach, cdh-5/PCDH15 and tgt-1/QTRT1 were selected for further
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investigation. Both genes have not been characterized in C. elegans; therefore, we should
understand their roles using null and hypermorphic alleles, with and without sensitized apl-1
backgrounds, in the future. In mammals, PCDH15 maintains cell-cell adhesion and
mechanotransduction (Richardson and Petit, 2019). We propose cdh-5 may be playing a similar
role in C. elegans—cdh-5 signal transduction may impact apl-1 signaling or CDH-5 and APL-1
may be working to maintain cell-cell adhesion, which we presume is lacking in apl-1(yn10)
mutants (Hornsten et al., 2007). While Huttlin et al. (2017) showed that QTRT1 physically
interacts with the APP family/Fe65 complex, the functional nature of this interaction is
unknown. We did not detect a physical interaction between APL-1 and TGT-1, suggesting this
may be a weak, transient interaction. Co-immunoprecipitation experiments should be conducted
to confirm this interaction.
Overall, our results point to several physical and genetic interactions involving APL1/APP family (Fig.1). We believe that we have identified interacting partners that can continue
inform the mammalian field.
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Figure 1. APL-1 interacts with multiple proteins physically and genetically. Cleavage by
secretases releases the APL-1 intracellular domain (AICD), which interacts with FEH-1 and
TGT-1. This complex is translocated to the nucleus where it transcribes some unknown genes.
UNC-52 sequesters sAPL-1, to allow local interaction with EAT-6/Na+-K+ ATPase, which
recruits nAChRs/AChRs. UNC-52 also places APL-1 in proximity to GPCRs and their exchange
factors through which signals are propagated. CDH-5/PCDH15, which is responsible for cellcell adhesion and mechanotransduction, may also be signaling through exchange factors,
mediated by APL-1.
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